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Abstract 
The platelet collagen receptor, GPVI, and podoplanin receptor, CLEC-2, have been 
shown to share a common tyrosine-kinase linked signalling pathway. GPVI contains 
a full ITAM (YxxLn6-12YxxL) within its intracellular tail, whilst CLEC-2 contains a 
hemITAM (YXXL). Both receptors rely on common, key signalling proteins including 
Src, Syk, LAT, Btk and PLCγ2, however the biological implications of GPVI and 
CLEC-2 stimulation are significantly different; GPVI is implicated in haemostasis and 
thrombosis responses whilst CLEC-2 appears to be involved in the newer roles of 
platelets, such as their roles in infection, immunity, and development.  It has also 
been shown that the organisation and importance of the signalling proteins in the 
pathway differ between GPVI and CLEC-2. The aims of this thesis are to explore 
the regulation and function of the tyrosine kinase-linked signalling pathway 
downstream of the two (hem)ITAM receptors in response to different stimuli at 
different stages of development. 
 
In this thesis, I show that both GPVI and CLEC-2 require an intact, functional Syk 
kinase domain of Syk to support signalling, regardless of the maintained 
phosphorylation of certain adapter docking sites. I also show that both GPVI and 
CLEC-2 are hyporeactive and expressed at lower levels on the platelet surface 
throughout development, and that these defects appear to be tyrosine kinase-linked 
pathway specific. Lastly, using samples from homozygous GPVI deficient patients, 
I have shown that both fibrin and fibrinogen appear to be agonists for GPVI. Overall, 
I have shown that are likely subtle differences in the regulation and downstream 
 
signalling of GPVI and CLEC-2 throughout development and to several different 
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1.1 Introduction to platelets 
1.1.1 A brief history of platelets 
 
Platelets are anucleate cells of the haematopoietic system, the first functional 
assessment and description of which is attributed to the Italian physician Giulio 
Bizzozero in the early 1880’s (14). Platelets are around three micrometres in diameter, 
have volumes of around ten femtolitres and have been found to circulate at 
concentrations of between 150-400,000 platelets per microlitre of blood; this small size 
and high abundancy originally led many to disregard platelets as unimportant ‘cellular 
dust’, or even to confuse them with fibrin clots or degenerated leukocytes (15, 16). 
However once Bizzozero performed his pioneering experiments – applying light 
pressure with a needle to arteries in the mesentery of anaesthetised animals – he 
observed platelets tethering at the site of damage. Initially only a few platelets arrived, 
however before long hundreds of platelets had aggregated and formed a thrombus 
which impaired the blood flow through the section of artery. This was the first time that 
this had been observed, and the first description of platelets playing an integral role in 
haemostasis (14, 16).  
 
Platelets were originally thought of solely as regulators of haemostasis and thrombosis 
for many years, and much of the initial research performed in the field focussed on this 
important function (17). However, Bizzozero himself hypothesised that cells with such 
a high blood concentration and ubiquitous expression must be involved not just in 
haemostasis and pathological thrombotic processes, but also in other physiological 
processes (14). Indeed, recent studies have shown that platelets play roles in 
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maintaining vascular integrity as well as in a number of developmental processes (18-
23); there is also evidence that platelets may play roles in a much wider range of 
pathophysiological processes such as inflammation, infection and immunity, and 
cancer metastasis (24-30). As platelets are second only to red blood cells in 
abundance, these newly uncovered roles may be extremely important in the 
pathophysiology of many diseases both inside and out of the cardiovascular system, 
just as Bizzozero hypothesised nearly 150 years ago.   
1.1.2 Platelet production 
 
In adults, platelets are produced from the cytoplasm of megakaryocytes (MKs) 
contained within the bone marrow (31, 32). MKs are polyploid cells around 50-100µm 
in size, around thirty times the size of the platelets that they produce, and are extremely 
rare; indeed most sources agree that they comprise less than 1% of all nucleated cells 
contained within the bone marrow (15, 33). As platelets have a lifespan of only around 
ten days, and during haemostatic challenge large numbers of platelets are consumed, 
MKs are required to be able to produce large numbers of platelets in extremely short 
periods of time (34). To produce platelets MKs respond to a plethora of stimuli, 
including thrombopoietin and sphingosine-1-phosphate, to initiate a process of 
megakaryocyte development and differentiation, subsequently resulting in a process 
of proplatelet formation, extension, release and eventual platelet release (15, 35, 36). 
During proplatelet formation, MKs form a number of elongated cytoplasm-containing 
membrane protrusions which migrate from the bone marrow into the lumen of nearby 
blood vessels (15). Once in the lumen, mature platelets begin budding from the tips of 
the proplatelet protrusions and enter the circulatory system (15). Each MK can form 
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between ten and twenty of these proplatelet protrusions, and thus each individual MK 
is capable of producing around 103 platelets (37).  
 
Interestingly, during embryogenesis and neonatal development, the sites and 
processes of thrombopoiesis are vastly different to those observed in adults (2-4). 
Initially platelet production occurs in the yolk sac of developing embryos, before moving 
to the liver and eventually to the bone marrow and spleen, which are the sites 
associated with adult thrombopoiesis; figure 1.1 details the timescales of 
thrombopoiesis migration throughout development (2-5). In mice, it has been shown 
that platelets can be first detected in the peripheral blood from embryonic (E) day 9.5 
and their numbers expand rapidly by E10.5 (5). Remarkably, a previously 
uncharacterised population of cells present in the yolk sac around these time points 
were discovered to share many MK-associated proteins, such as the thrombopoietin 
receptor Mpl, and were able to produce proplatelets (38). However, this newly 
discovered cell population appeared to be predominately diploid, compared with the 
polyploid MK cells found in adult bone marrow (38). This raises the possibility that 
platelet production may be inherently different during development, and also that the 
platelets produced by these MK-like cells in the yolk sac may differ from those derived 
from bone marrow MKs, as present in adults. It is also possible that platelet production 
at the other stages of development may be subtly different from that occurring in adults, 
and this may play a role in the previously observed altered functionality of embryonic 
and neonatal platelets (39-45). This is interesting to consider, particularly in light of 
more recent evidence which challenges the long-held belief that the bone marrow is 
responsible for the majority of platelet production in adults; for example the recent 
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paper by Lefrancais et al, building on previous work such as the study of Zucker-
Franklin and Phillip, proposes that MKs contained within the lung microcirculation are 
responsible for the production of around 50% of the circulating concentration of 
platelets (46, 47). Whilst more work is needed to replicate this finding, the idea that 
platelets may be derived from different locations in adults – similarly to that observed 
throughout development – raises interesting questions about the roles of each site and 
the similarity of platelets from each; a comparison of the composition and reactivity of 
platelets derived from different locations – such as bone-marrow MKs and lung 
microvasculature MKs – would therefore be extremely welcome.  
  











   
Figure 1.1 – Haematopoiesis and thrombopoiesis through development. Thrombopoiesis begins in 
the yolk sac, before moving to the liver and spleen, and finally localising to the bone marrow and 
lymph nodes. Sites of haematopoiesis throughout development graph adapted from Rodak’s 
Hematology: Clinical Principles and Applications (1-5) 
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1.1.3 Platelets in haemostasis 
 
 
The prototypical role of platelets, as mentioned, is in haemostasis and thrombosis. In 
their role as mediators of haemostasis, platelets circulate in a quiescent state in close 
proximity to the vascular endothelium; platelets are kept close to the vessel wall by the 
concurrent circulation of larger red blood cells, which force the platelets to the edges 
of the vessel (48). In healthy blood vessels, the endothelial cells lining the vessel are 
constantly releasing soluble mediators such as nitric oxide (NO) and prostaglandin I2 
(PGI2), also known as prostacyclin (49-51). These chemicals help to keep platelets in 
their quiescent circulating state by elevating intracellular levels of cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) (49-51). 
Elevation of cAMP and cGMP causes activation of protein kinase A (PKA) and G 
(PKG), respectively. PKA and PKG have a number of substrates within platelets that, 
upon becoming phosphorylated, dampen or downregulate a number of key regulators 
of platelet activation. For example, PKA has been shown to directly phosphorylate 
GP1bβ, causing a reduction in the ability of the GP1b-V-IX complex to bind to its 
substrate, von Willebrand factor (vWF), whilst PKG has been shown to phosphorylate 
the inositol triphosphate (IP3) receptor (IP3R), causing decreased Ca2+ release from 
IP3 sensitive stores (52-54). The above actions of PKA and PKG, alongside many 
more, result in platelets adopting an inactive, dormant state (54).  
 
Upon injury to the vasculature, endothelial cells coating the blood vessels are 
damaged, causing both a reduction in the production of PGI2 and NO and allowing 
platelets to come into contact with the sub-endothelial matrix (SEM). The SEM is a 
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mesh like structure containing a number of different pro-aggregatory proteins such as 
collagen(s), fibronectin, laminin and vWF (55). Platelets recognise and bind to a variety 
of these proteins via surface receptors such as GPVI and GP1b-IX-V – often in 
collaboration with adhesive receptors and integrins such as integrin α2β1 – allowing 
slowing, tethering and recruitment to the breach in the vessel wall, where they become 
activated. Initial platelet activation leads to the transduction of a variety of molecular 
signals, discussed in more detail below, culminating in the mobilisation of Ca2+ ions 
from intracellular stores, degranulation of intracellular vesicles and morphological 
changes (56). The shape change allows platelets to increase their surface area, 
spreading out over the damaged section of the vessel and forming the beginnings of a 
vascular plug, or thrombus (56). The release of granular contents and other platelet-
derived soluble mediators, such as ADP, thromboxane A2 and fibrinogen, plays an 
important positive feedback role, further strengthening the activation of the already 
adherent platelets alongside recruiting and activating other circulating platelets (56). 
Fibrinogen plays a particularly important role as it forms bridges between platelets 
through the integrin αIIbβ3, which holds the budding thrombus together at the site of 
injury (56); αIIbβ3 is present on platelets in a low-affinity conformation but upon Ca2+ 
mobilisation, undergoes a conformational change to a high-affinity state – this process 
is termed inside-out signalling. It is also a point of overlap between platelets and the 
coagulation system as the αIIbβ3 ligand, fibrinogen, is a key target for thrombin, which 
is a key player in both systems. Upon exposure to thrombin, fibrinogen is cleaved which 
allows it to be converted to fibrin (57), which is very important for clot retraction and full 
blockade of the vascular breach (58). This entire process occurs rapidly in response to 
vessel damage to arrest blood loss, and in the longer term to promote endothelial 
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growth and repair. Once the platelets have plugged the site of damage, they release a 
number of key angiogenic, inflammatory and tissue repair promoting factors (24, 59, 
60).  Key mediators such as vascular endothelial growth factor (VEGF), sCD40L and 
basic fibroblastic growth factor (bFGF) are all secreted from activated platelets (61-
64), aiding in immune function, vascularisation and endothelial cell proliferation at the 
site of damage.  
 
Due to the rapid initiation and propagation of platelet recruitment and activation, 
alongside the range of processes that platelets participate in, an active fibrinolytic 
system is required to prevent unwanted, pathological thrombosis. Without this system, 
inappropriate thrombosis would be able to occur unchecked, leading to serious and 
potentially catastrophic events such as pulmonary embolism (PE), myocardial 
infarction (MI), or stroke. To ensure effective prevention and speedy degradation of 
inappropriate thrombi, proteins and enzymes such as plasminogen/plasmin are 
actively released into the circulation and, upon contact with thrombi, perform functions 
such as the cleavage of fibrin molecules; plasmin is responsible for the cleavage of 
fibrin and is converted from plasminogen via enzymes such as urokinase and tissue 
plasminogen activator (tPA) (65). Processes such as fibrin cleavage prevent the 
growth and stabilisation of thrombi, releasing degradation products such as D-dimers 
(65, 66); D-dimer measurements are often used clinically as measures of fibrinolytic 
activity (65, 66). These degradation products, alongside the associated platelets, are 
then targeted for further degradation and clearance from the body. These processes 
are tightly controlled to prevent unwanted thrombosis whilst also allowing for 
physiological thrombus formation under haemostatic challenge (65). They are also the 
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same systems that are involved in the clearance of thrombi that have fulfilled their 
physiological purpose, however under these circumstances enzymes such as plasmin 
are activated in a highly localised response. This highly specific localisation is made 
possible due to the induced release of tPA and urokinase from the vascular 
endothelium via platelet-centred mechanisms such as induction of occlusive stress, 
thrombin stimulation and adrenaline release (65). Under physiological conditions, once 
the occlusive thrombus has been cleared and the vascular breach has been repaired, 
endothelial cells again release mediators such as NO and PGI2, restoring the 
equilibrium and once again ensuring platelets remain in a dormant, quiescent state.  
  
1.1.4 Platelets in thrombosis 
 
Although platelets are integral for arresting bleeding after trauma, the processes 
involved in prevention of blood loss can become abnormally activated in several 
pathophysiological conditions. Indeed, in 2015, ischemic heart disease and stroke 
accounted for 15 million, or 26%, of the 56.4 million deaths recorded world-wide 
throughout the year; these two conditions are consistently within the top 10 causes of 
death (67, 68). Virchow’s triad (figure 1.2) lists the three main interlinking causes of 
thrombosis: hypercoagulability, endothelial injury and blood stasis. When these 
conditions arise, aberrant platelet activation can occur, leading to the initiation of 
platelet aggregation and thrombus formation in the absence of any significant vessel 
damage; some examples of these conditions are obesity, atherosclerosis, cancer and 
even pregnancy (69-72). There are also numerous conditions whereby platelets 
behave normally in the initiation and retraction of thrombi, but where the machinery 
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used to breakdown and clear these clots once they have served their purpose is 
impaired; some examples of this are genetic mutations causing loss of function in 
proteins such as plasminogen, and acquired fibrinolytic disorders such as the 
development of auto-antibodies against key fibrinolytic proteins, including the pro-
fibrinolytic endothelial receptor, annexin A2 (73).   
 
Although thrombotic complications such as ischemic heart disease and stroke are 
consistently within the top ten causes of death worldwide, the true burden of 
cardiovascular disease can be seen in those that survive the initial cardiovascular 
events. For example, patients who survive initial ischemic strokes often develop severe 
life changing co-morbidities such as paralysis, vision and speech impairments, and 
memory loss. Not only is this a major burden on the patient and their families, in the 
long term, the specialist care required can put a large strain on local and national 
healthcare services. As mentioned above, aberrant thrombosis can lead to the 
development of both of these very severe, life-threatening conditions, clearly 
presenting a huge socio-economic burden (74-76).  
 
Although a number of the risk factors for aberrant thrombosis can be addressed by 
changes in lifestyle, for example diet changes to prevent atherosclerosis and changes 
in activity to prevent deep vein thrombosis (DVT) (77, 78), there are still factors that 
cannot be addressed by lifestyle choices. There are also points at which lifestyle 
choices alone cannot alleviate the risk of a severe cardiovascular event in patients who 
have developed cardiovascular diseases. This is where most research in the platelet 
field has been focussed to date, discovering new treatments and interventions to 
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prevent strokes and heart disease once risk factors become unmanageable by 
changes in lifestyle alone, or if the patient does not make the necessary changes to 
lifestyle (79). However, as has been found time and time again, it is extremely difficult 
to distinguish between pathological thrombosis and physiological haemostasis; most 
current treatment regimes, such as warfarin, aspirin or clopidogrel treatment, are a 
balancing act of preventing thrombotic complications whilst maintaining adequate 
haemostatic functionality to prevent catastrophic blood loss after trauma or injury. This 
ideal of being able to completely separate the physiological and pathophysiological 
functions of platelets has often been referred to as the ‘holy grail’ of platelet research 























Figure 1.2 - Virchow's Triad. Graphic shows the interplay between the three main overarching causes of both 
physiological and pathological thrombosis. Endothelial injury is traditionally thought of in terms of 
haemostasis, however diseases such as atherosclerosis can also cause endothelial damage and dysfunction, 
leading to unwanted thrombus formation. A number of conditions can induce a hypercoagulable state, where 
platelets are kept in a pre-activated state which increases the risk of pathological thrombosis. Blood stasis is 
the final member of the triad and is usually, but not solely, a result of a sedentary lifestyle. This immobility 
may be due to a number of factors such as age, obesity or even enforced bed rest after surgery. Usually, one 
of these risk factors alone is not enough to cause thrombotic disease, however when there is a large level of 
interplay between these risk factors, the risk of developing a thrombotic complication jumps dramatically (9-
13).  




Thrombocytopenia is defined as having a platelet count of ≤150x109 per litre of blood 
and can lead to various complications, the most severe being pathological 
haemorrhage. Thrombocytopenia can be thought of in rough ‘severity’ bands: 
• ≥150x109/l – Non-thrombocytopenic, non-symptomatic 
• 100-150x109/l – Mild thrombocytopenia, symptoms such as excessive bruising 
• 50-100x109/l – Moderate thrombocytopenia, symptoms such as excessive 
bleeding after traumatic events 
• ≤50x109/l – Severe thrombocytopenia, symptoms such as spontaneous internal 
and external bleeding (81) 
However, this classification is based solely on platelet count: qualitative changes in 
platelet reactivity can also influence the degree of bleeding. 
 
As can be seen from the information listed above, as platelet counts drop the ability of 
the haemostatic system to function falls in parallel. Patients with a severe 
thrombocytopenia presenting with spontaneous blood loss are considered a 
haematological emergency and often require intensive hospital treatment. There are 
several possible causes of thrombocytopenia and, other than in patients with genetic 
platelet defects or specific immune-mediated thrombocytopenias, is often detected as 
a secondary symptom of a separate pathology (82, 83). Conditions such as leukaemia, 
autoimmune disease and sepsis may all contribute to the development of 
thrombocytopenia (84-86), as may some of the drugs used to combat these disorders 
(87-89).  
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Typically, only patients presenting with severe thrombocytopenia will require treatment 
and currently the gold standard treatment is either platelet or whole blood transfusion 
(90), alongside treatment for the underlying cause of the low platelet count (91). 
However, in the last ten years, breakthroughs in the development of thrombopoietin 
(TPO) mimetics has opened the door for completely new treatment regimes. First 
generation TPO mimetics were unsuccessful in the clinic, not due to lack of efficacy, 
but due to a subset of patients developing a paradoxical thrombocytopenia in response 
to treatment with a PEGylated recombinant form of TPO (92). It was later discovered 
that these patients had generated IgGs against the recombinant protein which could 
cross-react with endogenous TPO and inhibit megakaryocyte development and 
differentiation (93). Although the safety profiles of first generation TPO mimetics were 
poor, the efficacy and potential applications of TPO mimetics were too good to pass 
up completely. Second generation TPO-based therapeutics aimed to maintain the high 
efficacy of first generations whilst improving their safety and side effect profiles. 
Several different avenues were explored to enable this leading to the development of 
three new classes of TPO-mimetic drugs: TPO peptide mimetics; TPO non-peptide 
mimetics; and TPO antibody mimetics (92). The two most commonly used TPO 
mimetics are romiplostim, a peptide mimetic given as a subcutaneous injection (94), 
and eltrombopag, a non-peptide mimetic given as an oral tablet (95). Romiplostim 
causes an increase in platelet count after single injections (94), whereas eltrombopag 
requires daily dosing for at least ten days to induce an increase in platelet count (95). 
TPO mimetics are becoming more common in the clinic, especially in the treatment of 
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immune thrombocytopenic purpura (ITP), however they have not yet become accepted 
as first line treatments for any diseases (92, 96, 97).  
1.1.6 Initial platelet activation in haemostasis and thrombosis 
 
As stated, during the haemostatic response, there is an initial wave of platelet adhesion 
and activation at the site of vascular damage, followed by a secondary wave of platelet 
recruitment, thrombus growth and eventual vascular plug formation. It has been 
determined that to perform these key functions, platelets have a number of key 
mechanisms controlling the instigation and subsequent reinforcement of their 
activation. Whilst the majority of the reinforcement of platelet signalling and activity is 
mediated by GPCR agonists, the initial adhesion and induction of platelet activation at 
sites of vascular damage is typically mediated by adhesion receptors and receptors 
that signal via tyrosine kinases. These GPCR and tyrosine kinase-linked pathways are 
discussed in more detail below. 
1.2 Platelet receptors in haemostasis and thrombosis  
1.2.1 Integrins 
 
There are five major integrins contained on the surface of platelets: α2β1 
(collagen), α5β1 (fibronectin), α6β1 (laminin), αvβ3 (vitronectin, fibrinogen, vWF, 
prothrombin, thrombospondin) and αIIbβ3 (fibrinogen, fibrin, vWF, fibronectin, 
vitronectin, thrombospondin) (98); there is also some evidence of ICAM-1 expression 
on platelets, which may be important in platelet-leukocyte interactions (98). αIIbβ3 is 
the most intensely studied integrin on platelets, likely due to its high levels of 
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expression – it is the most abundant integrin on platelets – alongside its important role 
in thrombus formation as the major fibrinogen binding receptor on platelets (98).  
 
Under resting conditions, platelet integrins are expressed on the cell surface in a low-
affinity conformational state, rendering them unable to bind to their substrates (99). 
However, upon platelet activation and intracellular calcium flux, integrins undergo what 
is known as inside-out activation. This inside-out activation of integrins, especially 
αIIbβ3, relies upon activation of a number of proteins, including PKC and CALDAG-
GEFI, to induce recruitment of proteins such as Talin-1 and Kindlin-3 to the intracellular 
tails of the integrins (99). This recruitment induces a conformational change in the 
integrin, allowing it to adopt a high affinity conformation and bind its substrate 
molecules. This whole process is dependent upon initial platelet signalling and 
subsequent Ca2+ mobilisation (99). There are only a few known integrin-based platelet 
disorders, with the most prominent being Glanzmann’s thrombasthenia. Glanzmann’s 
is characterised by defects in integrin αIIbβ3 expression or function and typically 
presents as a moderate to severe increase in mucosal bleeding (menorrhagia, 
epistaxis, gingival) and prolonged bleeding times, again highlighting the key role that 
αIIbβ3 plays in platelet function (100). 
1.2.2 G protein-coupled receptors  
 
G protein-coupled receptors are a large family of signalling proteins found on the 
membranes of a huge variety of cell types. They are characterised by seven trans-
membrane helices, an extracellular N-terminus and an intracellular C-terminus; the 
intracellular C-terminal tail is associated with the Gα and Gβγ protein subunits involved 
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in signal transduction. Under resting conditions, the Gα subunit is bound to GDP, 
causing association with the Gβγ subunit and the receptor itself. Upon agonist binding, 
a conformational change occurs which allows disassociation of the Gα and Gβγ 
subunits, both from the receptor and each other, alongside exchange of the GDP 
molecule for a molecule of GTP. Once this has occurred, both the Gα and Gβγ subunits 
move away from the receptor and can elicit their intracellular effects. The intracellular 
effects of Gα signalling are dependent upon the isoform of the protein; four key Gα 
isoforms are: Gαi (▼cAMP), Gαs (▲cAMP), Gαq (PLC activation) and Gα12/13 (Rho 
GTPase signalling). Gβγ subunits also appear to signal and whilst a large body of work 
suggests they appear to play important roles in the negative regulation and 
desensitisation of GPCRs, there is also some evidence that they may interact with 
phospholipases and phosphoinositide 3-kinase (PI3K). Some of the key GPCRs 
present on platelets – and their respective agonists – are:  
• Protease-activated receptors (PAR) [Thrombin] 
• Purinergic receptors (P2Y(n)) [ADP]  
• Prostacyclin receptors (IP) [PGI2] 
• Thromboxane A2 receptors (TP) [Thromboxane A2] 
A full list of all GPCR’s conclusively shown to be present upon the platelet surface can 
be found in table 1.1; GPCR’s for which mRNA has been identified but for which protein 
has not been subsequently confirmed to be present are omitted.  
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Table 1.1 – Table listing all G protein-coupled receptors (GPCRs) confirmed as present on the 
platelet surface and their main physiological agonists. Receptors with mRNA-level evidence but 
without confirmatory protein level analysis is are not listed (101). 
G-Protein Coupled Receptor Main Physiological Agonist(s) 
5-HT2a receptor Serotonin 
Adenosine A2a receptor Adenosine 
α2a-adrenoceptor Adrenaline, Noradrenaline 
Proteinase-activated receptor (PAR) 1 Thrombin 
Proteinase-activated receptor (PAR) 4 Thrombin 
Prostanoid IP1 receptor Prostacyclin  
Prostanoid EP3 receptor Prostaglandin 
Prostanoid TP-α receptor Thromboxane A2 
Purinergic P2Y1 receptor ADP 
Purinergic P2Y12 receptor ADP 
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1.2.2.1  PAR receptors 
 
PAR receptors are the key signalling receptors for thrombin contained on the surface 
of platelets (102). There are four isoforms of PAR receptors which may form both 
hetero- and homo-dimers; PAR1, PAR2, PAR3 and PAR4. All of these receptors 
isoforms have slightly different affinities, activation and signalling kinetics, and 
expression profiles, and the ability to form dimers is often important in their roles in 
platelet activation (103). The PAR family are present in an inhibited state on the surface 
of platelets but, upon contact with thrombin, the N-terminus is proteolytically cleaved. 
This cleavage causes the formation of a new N-terminus with an activatory sequence 
for the receptor which acts as a tethered ligand for PAR receptors and, once exposed, 
induces irreversible receptor activation (103).  
 
PAR1 is only expressed in human platelets and is not present in rodent platelets (104). 
PAR1 has a high affinity for thrombin and is responsible for fast but transient signal 
transduction. PAR3 appears to be only expressed in rodent platelets, and seems to act 
solely as a co-factor for PAR4 activation by thrombin, with no intrinsic G protein 
signalling capability (103-105); PAR1 also seems to be able to act as a PAR4 co-factor 
alongside its functional capability (103). PAR4 is expressed in both human and murine 
platelets, has a lower affinity for thrombin than PAR1 and PAR3, and is responsible for 
activation in response to high concentrations of thrombin (104); it accounts for slower 
but prolonged signal transduction and appears to play an important role in irreversible 
platelet aggregation.  
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All PAR isoforms play important roles in the activation of platelets, and as stated there 
is a complex level of interplay between the different receptor isoforms which can 
influence the signalling kinetics and specific transduction pathways involved in platelet 
function. For example, the formation of heterodimers of PAR1 and PAR4 on human 
platelets, and the observation that PAR4 is often cleaved secondarily to PAR1 via 
PAR1 bound thrombin, allows platelets to effectively respond to both low and high 
concentrations of thrombin (104). PARs appear to mainly signal through either the Gαq 
or Gα12/13 isoforms, activating either PLCβ – leading to PKC activation and IP3  
/DAG signalling – or Rho-GEF, both of which culminate in regulation of the platelet 
cytoskeleton and induction of platelet shape change (104). PAR antagonists have been 
developed and the PAR1 inhibitor vorapaxar has entered clinical trials. Vorapaxar has 
been shown to significantly reduce the risk of ischemic heart disease, however a 
significant increase in the rate of moderate-to-severe bleeding was observed when 
compared with standard care (106). Platelet PARs are extremely important receptors, 
and very attractive drug targets, however care must be taken as severe bleeding side 
effects may well present in patients treated with PAR inhibitors.  
1.2.2.2   P2Y(n) receptors 
 
The purinergic receptors contained on the platelet surface are a family of ADP and 
ATP-sensitive nucleotide receptors (107). The two-main platelet ADP-sensitive 
purinergic receptors which signal via G-proteins are P2Y1 and P2Y12; platelets also 
contain the P2X1 receptor which is a ligand-gated ion channel that responds to ATP 
(107). ADP and P2Y receptors have been shown to be extremely important in the 
haemostatic process; patients with defects in the storage or release of ADP, or in the 
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expression or function of P2Y receptors present with a mild-to-moderate bleeding 
diathesis (108, 109). 
 
P2Y1 is present on the platelet surface with a copy number of around 150 per platelet 
(104). It is coupled to the Gαq subunit and stimulates PKC and IP3/DAG downstream 
signalling via activation of PLCβ, culminating in shape change and Ca2+ mobilisation. 
P2Y1 signalling is also responsible for the downstream activation of PLA2 – which is a 
key step in the synthesis of thromboxane A2 from membrane-derived arachidonic acid 
(AA) – alongside activation of RhoA, providing a secondary mechanism by which it can 
drive platelet shape change (104, 107). P2Y1 appears to be most important in initial 
platelet activation, inducing shape change but only transient platelet aggregation (104). 
This, alongside its wide tissue distribution and low platelet-surface copy number, make 
P2Y1 a less appealing target for development of novel antithrombotic treatments than 
other platelet surface receptors. Indeed, whilst P2Y1 knock-out mice and 
pharmacological platelet P2Y1 inhibition experiments demonstrate impaired ADP-
induced platelet activation and reductions in thromboembolism, there do not currently 
appear to be any clinical studies exploring P2Y1 inhibitors as potential anti-thrombotic 
agents (110). 
 
P2Y12 is present at a copy number of around 600 per platelet, making it around four 
times more abundant at the platelet surface than P2Y1 (104). P2Y12 is coupled to the 
Gαi subunit, and thus stimulation of this receptor leads to the inhibition of adenylyl 
cyclase, leading to a decrease in the intracellular concentration of cAMP (102, 104, 
107). A reduction in the intracellular concentration of cAMP and subsequent inhibitory 
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pathways is associated with a pro-activatory state (102). Interestingly, the Gβγ subunit 
associated with the P2Y12 receptor also appears to be capable of activating PLCβ and 
PI3K, causing Ca2+ release and integrin activation (104, 107). These two 
complementary mechanisms may explain why P2Y12 stimulation contributes to a much 
stronger, irreversible platelet activation and aggregation than that seen with P2Y1 
stimulation. This fact, alongside the much more restricted expression profile of P2Y12, 
has made it a very attractive antithrombotic target, and has spawned potent platelet 
inhibitors such as cangrelor and ticagrelor which have proven successful in the clinic 
(104).  
1.2.2.3   Prostacyclin receptor 
 
The prostacyclin receptor has only a single isoform expressed on the surface of 
platelets, and is responsible for the inhibitory effects of PGI2 on platelets (102). The IP 
receptor is coupled to a Gαs subunit, causing an induction of adenylyl cyclase and 
subsequent increase in cAMP concentration upon PGI2 binding (102). Increased levels 
of cAMP in the platelet cytosol elicits a variety of pro-inhibitory effects, as previously 
described, and ensures that in the general circulation platelets are kept in a quiescent 
state (52, 53, 102). Platelets from mice deficient in the IP receptor have lower basal 
cAMP levels than WT controls and show a propensity to develop thrombotic 
complications in vivo. Interestingly, no differences in ex vivo reactivity were observed 
in the IP deficient mice, suggesting that cAMP levels are important for maintaining the 
resting state of platelets in vivo but does not predispose platelets to spontaneous 
activation (104, 111). Several IP receptor agonists have been developed and some, 
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such as iloprost, are currently used clinically for conditions such as pulmonary arterial 
hypertension (112).  
1.2.2.4   Thromboxane A2 receptors (TP) 
 
TP receptors are widely distributed throughout the body and respond to the chemical 
mediator thromboxane (Tx) A2 (113). In the context of platelets, upon activation TxA2 
is formed de novo from AA and released. AA, released from phospholipids in the 
plasma membrane via the activity of PLA2, is converted into TxA2 via the action of 
platelet cyclooxygenase (COX) enzymes (114). There is only one thromboxane A2 
receptor present on the platelet surface membrane – although two major splice 
variants have been proposed – which are coupled to both Gαq and Gα12/13 G-protein 
isoforms (102). There is also evidence that the two splice variants can have opposing 
effects, with the TPα variant causing stimulation of adenylyl cyclase and the TPβ 
variant inhibiting the same enzyme; most of this work has been performed in cell lines 
and expression systems and remains to be confirmed (102, 113).  
 
Upon binding to the TP receptor, TxA2 induces signalling through the PLCβ pathway 
(Gαq) and the Rho-ROCK signalling pathway (Gα12/13). As previously stated, 
activation of the PLCβ signalling pathway causes IP3 & DAG release, subsequent Ca2+ 
mobilisation and platelet responses including shape change and degranulation (113). 
Activation of the Rho-ROCK signalling pathways is responsible for downstream 
phosphorylation of myosin light chain, an important player in platelet membrane 
organisation. Phosphorylation of the myosin light chain can induce functional 
consequences such as platelet cytoskeleton reorganisation, shape change and 
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integrin activation (113). Although there is some interest in targeting the TP, the 
availability and efficacy of aspirin (a COX inhibitor preventing the conversion of AA to 
TxA2) as a platelet inhibitor potentially hampers the development of novel TxA2 or TP 
antagonists (115, 116).  
1.2.3 ITAM and hemITAM receptors 
1.2.3.1 ITAM and hemITAM motifs 
 
ITAMs are a highly conserved signalling motif of YxxI/L6-12YxxI/L present in many 
immune and antigen receptor signalling pathways (117). The tyrosine residues present 
in the ITAM domain become phosphorylated upon receptor activation and allow 
recruitment of Src-homology 2 (SH2) domain containing proteins, allowing the initiation 
of downstream signal transduction and cellular activation (117). A hemITAM motif is 
so named as it contains only one of the aforementioned YxxI/L amino acid sequences, 
in comparison to the full YxxI/L6-12YxxI/L contained in the traditional ITAM motif (118). 
HemITAM containing receptors typically function as dimers, which allows the formation 
of a ‘pseudo ITAM’ between the two monomeric receptor subunits (119).  
 
As suggested by the name, (hem)ITAMs are typically found within immune receptors 
located on the surface of immune cells such as B- and T-cells, neutrophils and platelets 
(120, 121). Although the motif is common between numerous receptors on many 
immune cell types, the functional responses downstream of these receptors can vary 
greatly, from induction of platelet activation and aggregation to playing an integral role 
in the maturation of B-cells (122, 123). Human platelets possess three major 
(hem)ITAM containing receptors and these are explored in more details below (124).  




GPVI is a 63 kDa immunoglobulin receptor, comprising 319 amino acids and 
expressed solely in the platelet and megakaryocytic cell lineage (125). It is the major 
signalling receptor for collagen contained on platelets (126) and is comprised of two 
linked extracellular domains, a highly glycosylated connector region (contributing 
largely to the molecular weight of the receptor), a trans-membrane domain and a 
relatively short intracellular tail. Linked to this intracellular tail is a dimer of the Fc 
receptor gamma chain (FcRγ) which contains the ITAM domains important for 
downstream signal transduction (126). GPVI contains a number of important motifs 
throughout that are involved in protein-protein interactions; for example the intracellular 
tail contains a motif allowing binding of Src family kinases (SFKs) whilst the trans-
membrane domain contains an arginine that is integral in linking GPVI to the FcRγ 
chain (127). A schematic of GPVI, alongside the other major platelet (hem)ITAM 
receptors, is present in figure 1.3. 
 
GPVI is mainly present on resting platelets as a monomer but upon activation forms 
dimers and begins to cluster in the membrane (128-130). The affinity of collagen for 
the monomeric form of GPVI is quite poor and it is unlikely that the levels of collagen 
present following the exposure of the sub-endothelial matrix – or the typically very low 
circulating concentrations (ng/ml) of serum collagen(s) – would be able to induce 
platelet activation solely via monomeric GPVI on the platelet surface (129, 131-134). 
This suggests an extremely important role for the dimerization and clustering of GPVI 
in the full and sustained activation of platelets in response to collagen (129-131). 
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Indeed more recent studies, including those from our group, have shown that a 
percentage of GPVI on resting platelets is present as the high affinity dimeric form, 
suggesting that dimer formation may be important for initiation of platelet activation via 
collagen with subsequent dimer clustering further increasing the signal (129, 130).  
 
When binding to collagen, an intracellular signalling cascade is initiated which 
culminates in platelet activation – including aggregation –  granule release and shape 
change (135). The first step in this pathway is the activation of Src family kinases 
(SFKs), particularly (but not limited to) Lyn and Fyn, which are a family of membrane 
bound proteins responsible for the phosphorylation of the tyrosine residues contained 
within the FcRγ-chain (126). This phosphorylation event allows the recruitment of 
spleen tyrosine kinase (Syk), a cytoplasmic kinase which plays an integral role in 
platelet signal transduction (126). Syk contains two Src-homology two domains (SH2), 
which allows it to bind to the phosphorylated tyrosine residues of the FcRγ-chain (136). 
This binding localises Syk to the plasma membrane and induces a conformational 
change, revealing a number of key residues within the molecule, whilst also exposing 
its kinase domain (137). Syk then undergoes a series of auto- and trans-
phosphorylation events (mediated by SFKs), resulting in full activation and further 
signal transduction (126, 137). Once activated, Syk phosphorylates a range of 
downstream proteins including the adapter protein linker of activation of T cells (LAT) 
which contains numerous tyrosine residues (126, 138). Phosphorylation of these 
residues by Syk provides docking sites for other important signalling proteins in the 
pathway, such as Gads, Grb2, SLP-76, Vav1/3, Btk, and PLCγ2; upon docking of these 
proteins the superstructure is often referred to as the LAT signalosome (126, 138). 
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One of the key end effectors of this signalling pathway is phospholipase C γ2 (PLCγ2), 
a lipase responsible for the formation of IP3 and DAG from the plasma membrane 
(126). A key responsibility for these two proteins is the mobilisation of intracellular Ca2+, 
which induces processes such as granule release, platelet shape change, and integrin 
activation (139). Platelet activation by collagen leads to spreading and coverage of the 
site of damage as well as forming a base for a developing thrombus. This signalling 
pathway is summarised in figure 1.4.  
 
GPVI has recently been shown to be a key signalling receptor for fibrin (140, 141). 
Mammadova-Bach, et al first noticed that patients with a deficiency in GPVI had a 
reduced peak in thrombin generation not only in response to collagen, but also in 
response to TF. This collagen-independent effect on thrombin generation was also 
observed in control platelets treated with a GPVI-blocking antibody, suggesting the 
possibility of a novel agonist for GPVI. This study also assessed spreading and 
thrombus formation; murine platelets deficient in GPVI and human platelets treated 
with a GPVI-blocking antibody fragment were assessed and both showed reductions 
in spreading on fibrin surfaces (141).  
 
At the same time, Alesheri, et al also published a study describing GPVI as a novel 
signalling receptor for fibrin (140). In their study, Alsheri, et al stimulated platelets with 
thrombin and fibrinogen in the presence and absence of GPRP (an inhibitor of fibrin 
polymerisation), functional αIIbβ3, and GPVI; αIIbβ3 was inhibited by both integrilin 
and genetic ablation, whereas GPVI functionality was removed via use of a deficient 
mouse model. It was shown that thrombin stimulation of platelets induces increased 
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platelet protein phosphorylation, but fibrinogen stimulation does not. Increases in 
tyrosine phosphorylation over that induced by thrombin alone were observed however, 
when thrombin and fibrinogen were co-administered to untreated platelets; the pattern 
of phosphorylation following co-stimulation mirrored that following GPVI stimulation. 
Addition of GPRP alongside thrombin and fibrinogen abolished the observed increase 
in phosphorylation. When αIIbβ3 was blocked or removed, the phosphorylation 
response to thrombin was abolished, whereas the response to thrombin and fibrinogen 
remained; in GPVI deficient mice, the increased phosphorylation in response to 
thrombin and fibrinogen was lost. These experiments were used to show that fibrin – 
formed by the co-administration of thrombin and fibrinogen – stimulates platelets in a 
pattern similar to that observed following GPVI stimulation. Following on from this, 
platelet spreading was assessed, and seen to be impaired in response to a fibrin 
coated surface in GPVI deficient mouse platelets; similar spreading results were 
observed in murine platelets treated with the SFK inhibitor dasatinib. Interestingly, no 
difference in spreading was observed on monomeric (+GPRP) vs polymeric fibrin (-
GPRP) coated surfaces, suggesting a common binding motif. They concluded their 
study using a FeCl3-induced thrombotic injury model, where impaired thrombus 
stability and increased time-to-occlusion was observed in GPVI deficient mice (140); 
both groups agreed that thrombus growth and stability is dependent upon the 
expression and function of GPVI on platelets (140, 141). 
 
These two landmark papers have opened up an entirely new avenue of research, and 
highlighted the importance of GPVI not just in the initiation but also in the propagation 
of thrombosis.  




CLEC-2, or the C-type lectin-like receptor 2, is a hemITAM containing glycoprotein also 
highly expressed on the surface of platelets (142, 143). This receptor does not appear 
to be restricted solely to the platelet and megakaryocytic lineage and has been 
identified on a small proportion of other immune cell types, however often at very low 
levels of expression (144, 145). There is some evidence that CLEC-2 expression may 
be induced at higher levels under specific conditions in some of these cell types, for 
example on dendritic cells stimulated with PDGF (146).   
 
CLEC-2 was initially identified in a bioinformatics screen performed by Colonna et al.  
in the year 2000 (147). This study identified CLEC-2 at the transcript level in dendritic 
cells (DC) and in the liver but it was not until 2006 that Suzuki-Inoue et al and Chaipan 
et al identified high levels of CLEC-2 protein in the platelet and megakaryocytic lineage 
(142, 147, 148). This was quickly followed up by evidence of CLEC-2 at both the 
transcript and protein level in the platelet and megakaryocyte lineage, in the study by 
Senis et al in 2007 (148).  
 
CLEC-2 belongs to the family of type II membrane proteins and comprises a 
carbohydrate-like recognition domain, trans-membrane domain and intracellular tail, 
the latter of which contains the hemITAM motif (Figure 2) (142, 148). Interestingly – 
although CLEC-2 contains a hemITAM – the receptor is active as a dimer, suggesting 
that SH2 containing proteins may be able to form a ‘pseudo’ ITAM by binding one YxxL 
repeat from each receptor (149); however, little work has been performed exploring 
this as a potential signalling mechanism. Another important difference between CLEC-
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2 and GPVI is the importance of a tri-acidic amino acid sequence directly upstream of 
the hemITAM; these three acidic amino acid residues are present upstream of the YxxL 
repeat in several other hemITAM containing receptors (150). Currently, it appears that 
no tri-acidic amino acid sequences are found proximally in ITAM receptors in 
mammals. These amino acids are required for phosphorylation of the YxxL sequence 
present in hemITAM receptors (150).  
 
CLEC-2 signals via the same set of signalling proteins as the ITAM receptor GPVI 
(figure 1.4), however as with the motif itself there are a number of key differences in 
the signal transduction. Initially, whereas GPVI is reliant upon SFKs for the initial 
phosphorylation of the ITAM, the hemITAM contained within CLEC-2 seems to rely 
much more heavily upon Syk for initial phosphorylation (151, 152). Severin et al, 
building upon the work of Spalton et al, showed that in the absence of the major platelet 
SFKs – Lyn, Fyn and Src – CLEC-2 phosphorylation still occurred, but was abolished 
in the absence of Syk (151, 152). However, SFKs are required for the downstream 
signal transduction as, although CLEC-2 phosphorylation is unaffected, PLCγ2 and 
platelet aggregation is impaired in the absence of SFKs (151). In an alternative model, 
Manne et al reported that inhibition of PI3K and/or Tec family kinases abolishes CLEC-
2, but not GPVI, mediated Syk phosphorylation and platelet activation (153) and 
proposed that Tec/Btk and PI3K lie upstream of Syk and directly regulate its function 
in the CLEC-2 signalling pathway (153). Interestingly, these studies seem to suggest 
that, while GPVI and CLEC-2 utilise the same signalling proteins and pathway, there 
appear to be subtle yet significant differences between the exact organisation and 
contribution of each signalling protein between GPVI and CLEC-2. 
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The endogenous ligand for CLEC-2 has been identified as podoplanin. A 43-kDa 
protein was discovered in a number of different cell types throughout the 1990s, 
including lymphatic endothelial cells, fibroblastic reticular cells, and thymic epithelial 
cells, amongst others (154). However as many different groups were working on the 
protein at the same time it has had many different names such as GP38, E11 antigen 
and OTS-8 amongst others (154). The name podoplanin was coined in 1997 by 
Breiteneder-Geleff et al, due to its expression on kidney podocytes and possible role 
in podocyte foot flattening processes (155). As mentioned, podoplanin was found to 
be expressed in a number of different cell types and tissues, and one area where 
podoplanin is particularly highly expressed is on lymphatic endothelial cells (LECs) 
(154, 156). Expression of podoplanin on LECs, and its interaction with CLEC-2 on the 
surface of platelets, is especially important during development, where it has been 
shown to aid in the separation of the lymphatic and vascular systems (157). It has been 
shown in several studies that mice lacking CLEC-2, proteins involved in the CLEC-2 
signalling pathway, or podoplanin have a number of severe phenotypes associated 
with defective lymphatic development (21, 157-160). In utero, the embryonic mice are 
oedematous and present with bleeds in the brain, developing lymphatic system and 
sometimes in the skin (159, 161). Those mice that survive go on to develop numerous 
physiological defects such as blood filled lymph nodes and vessels (especially 
noticeable in the mesentery) and chylous ascities (an accumulation of milky chyle in 
the peritoneum associated with defective lymphatic function) (159). The fact that this 
phenotype is present in mice lacking platelet CLEC-2, alongside evidence such as 
phenotype reconstitution in embryos treated with platelet inhibitors or with genetic 
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ablation of CLEC-2 signalling proteins, is indicative of an integral role for platelets in 
lymphatic development and subsequent separation from the vasculature (157, 159). It 
also provided one of the first important pieces of evidence supporting the role of 
platelets as important mediators of processes outside of haemostasis and thrombosis. 




FcγRIIa is the final (hem)ITAM receptor present on human, but not mouse platelets 
(162, 163). FcγRIIa belongs to the Fc superfamily of receptors found on many different 
cells types, especially cells involved in infection and immunity, that recognise the 
constant Fc region of antibodies when bound to their target antigens (162, 164). 
FcγRIIa specifically binds to antibodies expressing an IgG Fc region and appears to be 
restricted in evolutionary expression to higher primates alone (162, 164).  
 
The first mention of FcγRIIa in the literature was in the 1980’s, and it was in 1985 that 
the receptor was first identified on human platelets (165). It is a type I trans-membrane 
glycoprotein with a general structure that is unique only to FcγRIIa and FcγRIIc (164, 
166). Most Fc receptors are multimeric whereas FcγRIIa is a single chain receptor 
comprising two IgG-like extracellular domains, a trans-membrane domain and a 
cytoplasmic tail (164, 166). The cytoplasmic tail contains the ITAM motif enabling 
signal transduction downstream of the receptor (Figure 2).  
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The presence of FcγRIIa on human platelets supports the idea that platelets may be 
important mediators of immunity however, as the protein is not expressed in the rodent 








Figure 1.3 - (hem)ITAM receptors present on the surface of platelets. CLEC-2 amd GPVI  are 
expressed in both human and murine platelets, whereas FcγRIIa is only expressed in human 
platelets. All three receptors contain at least one YxxL repeat in their intracellular tail which is the 
key motif for downstream signal transduction.  
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1.3 Key GPVI and CLEC-2 signalling proteins 
1.3.1 Key proteins overview 
 
As stated above, there are numerous key signalling proteins involved in (hem)ITAM 
signal transduction. Proteins such as SFKs and Syk are integral for initiation and 
proximal signalling events, as evidenced by the lack of signal transduction and platelet 
aggregation in the absence or inhibition of these proteins (151, 152). Surprisingly, 
although LAT would appear to play an essential adapter role, it is actually dispensable 
for platelet activation, with the caveat that loss of LAT dampens platelet responses and 
impairs thrombus formation (167). This is in comparison to the almost complete loss of 
GPVI signal transduction in the absence of the adapter SLP-76 and loss of both VAV1 
and VAV3 (168, 169); interestingly, mice deficient in SLP-76 show defective lymphatic 
development, reminiscent of that seen in mice with severe deficits in the CLEC-2 
signalling pathway (160). Other adapter proteins such as Gads appear to play less 
important roles in (hem)ITAM signal transduction (167). Downstream kinases, such as 
Btk and PI3K, also play particularly important roles in (hem)ITAM signal transduction, 
although their signalling contributions may be different depending on the receptor 
engaged (153); remarkably, mice deficient in the Tec family kinases Btk and Tec again 
recapitulate the developmental defects of mice deficient in CLEC-2, suggesting a 
particularly important role for both of these kinases downstream of the hemITAM 
receptor (153). Lastly, as stated above, the end effector of these pathways is PLCγ2, 
which is responsible for IP3 and DAG formation and subsequent Ca2+ mobilisation. This 
protein is almost entirely indispensable for both GPVI and CLEC-2 induced platelet 
activation, as seen in mice deficient in PLCγ2 (142, 170).  




Figure 1.4 – Key signalling proteins and events downstream of the platelet (hem)ITAM receptors GPVI and CLEC-2. Upon receptor engagement via endogenous 
or exogenous ligands, SFKs are activated and phosphorylate tyrosine residues contained within the (hem)ITAM, allowing recruitment of Syk. Upon recruitment, 
Syk undergoes both trans- and auto-phosphorylation events, allowing full activation of the protein and phosphorylation of downstream proteins such as LAT; 
Syk can also positively feedback and phosphorylate the hemITAM contained within CLEC-2. Once LAT is phosphorylated, other proteins such as PI3K, SLP-76, 
Btk and PLCg2 are recruited and docked to LAT to form the ‘LAT signalosome’. These proteins undergo several subsequent phosphorylation events, culminating 
in the activation of PLCg2. Activation of PLCg2 results in the lipolysis of PIP3 to PIP2, releasing IP3 and DAG which induces Ca2+ mobilisation and PKC activation, 
causing full platelet activation.  




Syk is a 72kDa cytoplasmic protein that is ubiquitously expressed in cells of the 
haematopoietic system; the only haematopoietic cells not expressing Syk, namely 
T-cells and natural killer (NK) cells, express a homologous protein known as ZAP-
70 (8, 137, 171). Syk expression is highly conserved between almost all species of 
vertebrate with a decidedly similar structure, for example the main isoforms of Syk 
expressed in Homo sapiens and Mus musculus (common house mouse) differ by 
only six amino acids (172). Syk is comprised of two SH2 domains (N-SH2 and C-
SH2) linked together by an amino acid linker region (linker A) (8). The C-terminal 
SH2 domain is then linked to a kinase domain via a second amino acid linker region 
(linker B) (8). There are also a number of serine, threonine and tyrosine amino acid 
residues dispersed throughout the protein which are extremely important in the 
regulation of Syk activity (173). Some residues, such as the dual tyrosine residues 
Y525/526 (murine Y519/520) located within the Syk kinase domain, are important 
for regulating the activity of Syk as a functional kinase (174, 175). Other residues, 
including Y323 (murine Y317) and Y352 (murine Y346), play important positive and 
negative adapter roles. For example, phosphorylation of Y323 has been shown to 
provide a docking site for the negative regulatory proteins c-Cbl (a ubiquitin ligase) 
and TULA-2 (a phosphatase); docking of these proteins to Syk has been shown to 
regulate the magnitude of Syk responsiveness to stimulation (176-180). 
Phosphorylation of Y352 on the other hand has been hypothesised to be an 
important docking site for many other proteins involved in signal transduction 
through the Syk pathway (179-183). Schematics representing the regulation of Syk 
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and detailing the key regulatory domains as well as several key tyrosine residues, 
can be seen in figures 1.5 and 1.6. 
 
Under resting conditions, Syk is held in an autoinhibited state which restricts its 
ability to function. Although the exact mechanism by which Syk is autoinhibited has 
not been fully elucidated, the crystal structure of an autoinhibited Zap-70 molecule 
has been generated (184). As Syk and Zap-70 have very similar structures and 
functions, it is believed that the mechanism of autoinhibition is likely to be conserved 
(182). In this model, several intra-molecular bonds between linker A, linker B and 
the kinase domain of Syk form an interface which has been termed the ‘linker-kinase 
sandwich’ (184). This ‘sandwich’ holds the protein in a conformation which has a 
three-fold mechanism of inhibition. Firstly, the SH2 domains are pushed out of the 
alignment which allows them to efficiently bind to a phosphorylated ITAM domain; 
secondly, the kinase domain is forced out of its optimal arrangement resulting in a 
decreased ability to catalyse the phospho-transfer reaction; and finally, many of the 
important tyrosine residues mentioned above reside within, or extremely close to, 
the regions involved in the formation of the ‘linker-kinase sandwich’ and, as a result, 
are unable to become phosphorylated prior to conformational change (184-186). It 
is thought that the mechanism of autoinhibition of Syk is identical to that of Zap-70, 
as many of the residues that have been identified to be important in autoinhibition 
of Zap-70 are in the same relative locations within the Syk molecule, and the two 
proteins are structurally very similar (6, 184). However, without resources such as 
crystal structures this hypothesis remains to be definitively proven.  
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Upon coming into contact with a fully phosphorylated (hem)ITAM domain, it 
becomes energetically favourable for Syk to become stabilised in an active 
conformation (8, 186). Once this occurs, the protein induces calcium mobilisation 
and subsequent platelet activation as described above. 
 
With regards to (hem)ITAM signalling, it is interesting to consider Syk as a potential 
point of divergence in the signal transduction machinery between GPVI and CLEC-
2. It has been shown that CLEC-2 is much more dependent upon Syk for initial 
hemITAM phosphorylation, compared to SFKs filling this role downstream of GPVI 
(151, 152). As stated above, there is also evidence that proteins such as Btk and 
PI3K may impact on Syk signalling at different points within GPVI and CLEC-2 the 
signalling cascades (153). Lastly, due to the presence of potentially differentially 
phosphorylatable tyrosine residues distributed throughout the protein, this raises a 
possible mechanistic role for Syk in the differential effects of GPVI and CLEC-2 
receptor engagement (180).  
  










Figure 1.5 – Regulation of Syk activity via changes in conformation. Ths figure highlights (a) the crystal 
structure of Syk in complex with its non-hydrolysable substrate AMP-PNP, adapted from Gradler et al. (b) 
Mechanisms of Syk activation from an auto-inhibited, inactive state to an open, active, signalling structure 
via auto- and trans-phosphorylation and binding to phosphorylated SH2 domain-containing proteins, 
adapted from Kulathu et al and Mocsai et al (6-8).  




LAT, or linker of activation of T-cells, is a ~36 kDa adapter protein involved in the 
platelet (hem)ITAM signalling pathway. As its name implies LAT was first discovered 
in T-cells in the early 90’s, however it was only in 1998 the protein was cloned from 
stimulated Jurkat cells expressing the TCR (187). Initially, this 36-38 kDa protein 
was of interest as it provided a link between initiation of T-cell receptor signalling 
and T-cell activation – it was shown to be one of the most prominently 
phosphorylated proteins present after T-cell receptor stimulation (187). The protein 
was also known to be membrane bound and associated with other key signalling 
proteins in the TCR pathway, such as Grb2 and PLCγ1 (187). It was these 
characteristics that allowed Zhang et al to be confident of the identity of this newly 
cloned protein. Once cloned, the protein was named after its key signalling role – 
linking TCR engagement to T-cell activation (187).  
 
The main human isoform of LAT contains 262 amino acids, and the sequence is 
highly conserved between species. The domain composition of the protein is also 
identical between species, containing a very short extracellular domain, a 
transmembrane region and a large intracellular domain (188). Within the intracellular 
domain there are a number of phosphorylatable amino acids, of which 10 are 
tyrosine residues, 31 are serine residues, and 11 are threonine residues. This high 
percentage of phosphorylatable amino acids highlights the key adaptor role that LAT 
plays in the (hem)ITAM signalling pathways – indeed many publications cite the 
‘LAT signalosome’, reiterating the key structural nature of the protein (167). 
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Phosphorylation of these amino acids, particularly the tyrosine residues, by proteins 
such as SFKs and Syk allows the docking of various other key SH2-containing 
signalling molecules, such as Grb2, Vav1 and PLCγ1 & 2, and facilitates their 
localisation to the plasma membrane (167, 188, 189). This ability to localise proteins 
to the membrane is particularly important as it allows effectors such as PLCγ2 to 
elicit their effects, typically resulting in cell activation (188). It has also been shown 
that each of the tyrosine residues within the molecule appears to provide a distinct 
docking site allowing for recruitment of specific proteins; for example, 
phosphorylation of Y136 appears to allow recruitment and docking of PLC (189). A 
schematic showing the structure and position of a number of these key tyrosine 
residues can be seen in figure 1.6.  
 
After the cloning of LAT, it was discovered that it may be involved in signal 
transduction in other haematopoietic cells containing tyrosine-kinase based 
signalling cascades, such as platelets (190). Indeed, phosphorylation of LAT was 
observed in platelets, and was much more potent following stimulation via GPVI 
compared with the GPCR-mediated response to thrombin (191). Since these initial 
descriptions of LAT and its role in platelet function much work has shown that LAT 
plays an important role in full platelet activation, particularly downstream of 
(hem)ITAM receptor induction (167, 192). For example LAT plays a key role in 
maximal platelet activation downstream of GPVI and CLEC-2, although residual 
activatory responses are observed following genetic ablation of LAT (167).  
 




Phospholipase C gamma 2 (PLCγ2) is a ~148kDa protein with particularly high 
expression in the haematopoietic lineage and the liver; in contrast the other PLCγ 
isoform, PLCγ1, has a much more ubiquitous expression profile (193). PLC enzymes 
have been mentioned in the literature as early as the 1960’s. PLCγ2 is a member of 
the phospholipase family of enzymes, which catalyse the cleavage of phospholipids 
from the plasma membrane (193). The products of this phospholipid cleavage 
include bioactive products which are responsible for Ca2+ mobilisation and PKC 
activation (193-195). Ca2+ mobilisation and PKC activation result in the activation of 
cellular responses; in the context of platelets these two events are responsible for 
responses such as vesicle secretion, actin polymerisation and platelet spreading 
(196-198). For these reasons, PLCγ2 is often referred to as an end effector of these 
signalling pathways.  
 
Similarly to Syk, LAT and other proteins in this signalling pathway, PLCγ2 has a 
number of phosphorylatable residues contained throughout the molecule, including 
several tyrosine amino acids. These tyrosine residues appear to be phosphorylated 
by Bruton’s tyrosine kinase (Btk), another key component of the LAT signalosome, 
and SFKs (199-201). It has also been suggested that, similarly to the other proteins 
already discussed, each tyrosine residue may play an individual functional role upon 
phosphorylation. Two key tyrosine residues that have been characterised to date 
are Y759 and Y1217 (199, 202). Phosphorylation of these tyrosine residues appears 
to be important for the interaction of PLCγ2 with its activatory proteins, as well as 
correlated with full activation of its catalytic activity (202, 203). Again, a schematic 
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showing the structure of PLCγ2, alongside the location of several key domains and 
tyrosine residues, can be seen in figure 1.6.  
 
As with the majority of important signalling proteins, a number of different genetically 
modified mouse models have been generated and used to explore the function and 
distribution of PLCγ2. Using different genetic mutations and specific targeting 
techniques PLCγ2 has been shown to play a vital role, not just in platelets, but in 
cells such as B- and T-cells as well (204); there is also some evidence that PLCγ2 
may also be important in other cell types, such as osteoclasts, and processes such 
as maintenance of basal bone mass (205, 206). Platelets from mice lacking PLCγ2 
show a significant reduction in response to collagen, and no response to CRP or 
convulxin stimulation. However, these PLCγ2 deficient platelets respond normally 
to stimuli that do not signal via tyrosine-kinase linked signalling pathways, for 
example ADP and thrombin (170). These mice are also seen to exhibit defects in 
physiological haemostasis, as measured by a prolonged tail bleeding time, and often 
present with other physiological defects such as retarded growth; these mice also 
exhibit a degree of perinatal lethality, possibly linked to the deficits in physiological 
haemostasis during development (204). All of the studies performed using these 
transgenic mice have highlighted an extremely important role for PLCγ2, not just in 
platelet function, but also in critical processes such as immune system function and 




















Figure 1.6 - Schematics showing the structure of Syk, LAT and PLCγ2. All domains have been listed, 
alongside a selection of the most important tyrosine residues involved in signal transduction.  
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1.4 Platelets outside of thrombosis and haemostasis 
 
As shown above platelets play an indispensable role in the physiology and 
pathophysiology of haemostasis and thrombosis, however there is an increasing 
recognition of the role of platelets beyond these processes. Platelets have recently 
been shown to be important in a diverse range of processes and diseases, including 
inflammation, infection, immunity, cancer and development. 
  
In cancer, platelets have been shown to play a number of different pro-cancerous 
roles (30, 207-210). Platelets contain large stores of pro-angiogenic factors, and the 
endothelium of cancerous cells is phenotypically more favourable for platelet 
adhesion and activation – for example increased tissue factor (TF), a potent platelet 
activator, has been observed in numerous types of cancer (207). This increased 
recruitment and activation of platelets in at cancerous sites allows local release of 
factors such as vascular endothelial growth factor (VEGF) which may help promote 
vascularisation of tumours (207).  
 
Platelets have also been implicated in almost all stages of cancer metastasis. 
Platelets can come into contact with metastatic circulating tumour cells (CTCs) in 
the vasculature and become activated (207). Upon activation, platelets adhere to 
the CTCs via mechanisms such as fibrinogen-αIIbβ3 interactions and P-selectin 
binding. This coating of platelets is thought to protect the CTCs from destruction by 
immune cells through multiple mechanisms; for example by providing a mechanical 
‘shield’ for CTCs and preventing direct contact the CTCs and cells such as natural 
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killer (NK) cells (207, 209, 211). Platelets may also aid CTC extravasation via a 
number of mechanisms including the harnessing of platelet-derived selectins, such 
as P-selectin (209).  
 
The above pro-cancerous mechanisms of platelets suggest that, under certain 
circumstances, modulation of platelets and their reactivity may be beneficial in the 
treatment of certain cancers (212). Indeed, whilst there is a small level of 
disagreement in the literature, several meta-analyses and systematic reviews have 
highlighted a potential benefit of anti-platelet therapies – such as aspirin and/or 
clopidogrel – in both the treatment and prevention of cancer; the level of benefit 
does appear to depend upon the type of cancer, with the incidence of cancers such 
as colorectal and breast cancer appearing to react strongly to treatment with anti-
platelet drugs (213-216). Whilst several of these retrospective studies have 
assessed clinical studies of anti-platelet therapies in cancer, the majority of these 
seem to have been performed with aspirin and, although the benefits seen with 
aspirin appear to be shared by other anti-platelet therapeutics such as clopidogrel, 
further clinical assessments are still required; there are currently a number of 
ongoing clinical studies exploring the use of anti-platelet therapies in cancer, some 
of which are listed on clinicaltrials.gov.  
 
Platelets have also been shown to be important mediators of inflammation and 
inflammatory diseases, such as systemic lupus erythematosus (SLE) and 
rheumatoid arthritis (RA) (217). The role of platelets in RA was not initially expected, 
however the presence of platelet-derived microparticles in the synovial fluid of RA 
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patients alongside the finding that depletion of platelets prevents increases in 
synovial endothelium permeability present the possibility that they may be important 
in the pathophysiology of this disease (217, 218). Furthermore, it was shown that 
serotonin released from platelets stimulated with intravenously injected collagen 
related peptide (CRP) was responsible for driving increased vascular permeability 
in RA patients (217-219). These findings suggest an important role for platelets in 
the progression of arthritic disease.  
 
More recently, it has been shown that other cell types, particularly those involved in 
the immune system, can up-regulate the expression of podoplanin under certain 
stimuli (148, 220). One example of this is the finding that platelets can interact with 
agonistic molecules present on the surface of M1 polarised, inflammatory 
macrophages to become activated; the majority of these interactions are mediated 
via the podoplanin-CLEC-2 axis. One result of these interactions is an increase in 
the secretion of many pro-inflammatory cytokines such as TNFα and IL-23 from 
macrophages (221). This is particularly interesting to consider in the context of 
atherosclerotic plaque formation, where macrophages play a particularly important 
role, and where they are extremely likely to encounter platelets (222). The possibility 
of platelets inducing macrophages to release cytokines which will further reinforce 
the recruitment of M1 macrophages which then take up oxidised low-density 
lipoproteins (oxLDL) and become foam cells – these foam cells make up the majority 
of the atherosclerotic plaque (222-224). This interaction is also important as when 
atherosclerotic plaques rupture, they release numerous pro-thrombotic molecules, 
alongside exposing sub-endothelial proteins such as collagen (225); atherosclerotic 
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plaque rupture is a major risk factor for the development of thrombotic complications 
such as MI or stroke (226, 227).  
 
Possibly the most surprising discovery was the importance of platelets throughout 
development, particularly in the development and separation of the blood and 
lymphatic circulatory systems as described above (21, 157-161). This may be one 
of the most novel and exciting fields of platelet research, especially when considered 
alongside observations such as a marked increase in the incidence rate of 
intraventricular haemorrhage in pre-term neonates (228).   
 
It is of particular interest in the field that many of these novel functions of platelets 
outside of traditional haemostasis and thrombosis appear to be strongly mediated 
by the hemITAM receptors, GPVI and CLEC-2. 
 
1.5 Aims  
 
Whilst the proteins involved in the GPVI and CLEC-2 signalling pathways are well 
established; the above information highlights significant differences between both 
the initiation of signalling and the functional consequences following stimulation of 
these two receptors. This raises the possibility that there may be differences within 
the signalling pathways themselves which can partially account for the functional 
differences. Considering this, there are three main inter-related aims of this thesis: 
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1. Investigation of a possible adapter role for Syk, and exploration of specific 
tyrosine phosphorylation events on key signalling proteins, using a novel 
transgenic mouse model 
1.1 Hypothesis – Syk has a role as an adapter protein independent of 
its role as a kinase, and this adapter function can support a level 
of signal transduction and platelet activity in the absence of any 
kinase functionality 
2. Exploration of neonatal platelet hyporeactivity, and determination of whether 
known hyporesponsiveness to collagen extends to platelet stimulation with 
CLEC-2 agonists 
2.1 Hypothesis – Neonatal platelets are hyporeactive to both GPVI 
and CLEC-2 stimulation due to an underlying, common signalling 
defect 
3. Investigation of fibrin as a novel ligand for GPVI 









Materials and Methods 





Details of the reagents used throughout the course of this thesis are listed in the 
tables below. Table 1 lists the platelet agonists used, table 2 the platelet antagonists, 
and table 3 any antibodies and fluorescent stains used. If not otherwise stated, 
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Table 2.1 - Agonists 
Agonist Target/s Source 
α-CLEC-2 mAb (17D9) CLEC-2 Bio-Rad (Kidlington, UK) 
ADP P2Y1 
P2Y12 
Sigma (Poole, UK) 
Collagen (Horm) GPVI 
α2β1 
Nicomed (Linz, Austria) 
Collagen Related Peptide 
(CRP) 








Laboratories (Swansea, UK) 
Human PAR-4 Peptide 
(Sequence: AYPGKF) 
PAR-4 AltaBioscience (Birmingham, 
UK) 
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Table 2.2 - Antagonists 
Antagonist Target/s Source 
Dasatinib Src 
BCR/Abl 
Sigma (Poole, UK) 
Forskolin cAMP Sigma (Poole, UK) 
Heparin Thrombin 
FXa 
Sigma (Poole, UK) 
PP2 Src Sigma (Poole, UK) 
PRT-060318 Syk Portola Pharmaceuticals Inc 
(San Francisco, CA) 
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Table 2.3 - Antibodies and fluorescent stains 
Antibody/Stain Target/s Working 
Concentration 
Source 
α-βTubulin Beta Tubulin 10µg/ml Sigma (Poole, UK) 
α-CLEC-2*FITC CLEC-2 3 µg/ml AbD Serotec 
(Kidlington, UK) 
α-CLEC-2 (17D9) CLEC-2 1µg/ml Bio-Rad (Kidlington, 
UK) 
Fibrinogen*Alexa 488 Fibrinogen binding 
(activated aIIbb3) 
50µg/ml Life Technologies 
(Madrid, Spain) 
α-CD42b-FITC GP1bα 1/30 dil 
(Cat No. M042-1) 
Emfret (Eibelstadt, 
Germany) 
α-GP1bα GP1bα (Immune 
Depletion) 
1.5µg/g Emfret (Eibelstadt, 
Germany) 
α-GPVI GPVI 1µg/ml Dr E. Gardiner 
(Canberra, Australia) 
α-GPVI*FITC GPVI 1/30 dil 
(Cat No. M011-1) 
Emfret (Eibelstadt, 
Germany) 
α-IgG*FITC IgG 1/30 dil 
(Cat No. P190-1) 
Emfret (Eibelstadt, 
Germany) 
α-IgG IgG (Immune Depletion 
Control) 
1.5 µg/g Emfret (Eibelstadt, 
Germany) 







LAT Y171 (human no.) 
 
1/1000 dil 
(Cat No. 3581) 
 Cell Signalling 
Technology (Leiden, 
The Netherlands) 
α-LAT Y191 LAT Y191 (human no.) 1/1000 dil 






LAT Y132 (human no.) 
 
1/1000 dil 
(Cat No. ab4476) 
Abcam (Cambridge, 
UK) 
α-LAT Y200 LAT Y200 (human no.) 1/1000 dil 






















α-PLCγ2 (Q-20, rabbit 
mAb) 
PLCγ2 1/1000 dil 
















α-PLCγ2 Y759 PLCγ2 Y759 (human 
no.) 
1/1000 dil 








Rat IgG 20µg/ml Fischer Scientific 
(Loughborough, UK) 
α-Syk (4D10) Syk 1/1000 dil 






Syk Y323 (human no.) 
 
1/1000 dil 






Syk Y352 (human no.) 
 
1/1000 dil 




α-Syk Y525/526 Syk Y525/526 (human 
no.) 
1/1000 dil 




α-CD49b*FITC α2β1 1/5 dil 
(Cat No. M070-1) 
Emfret (Eibelstadt, 
Germany) 
α-CD41a*PE αIIbβ3 1/30 dil 
(Cat No. 561850) 
BD Pharmigen 
(Oxford, UK) 





α-CD41/61-FITC αIIbβ3 1/30 dil 
















Syk K396R (SykK396R,fl/fl) mice were generated by and obtained from Taconic 
Biosciences (Cologne, Germany), using the targeting strategy outlined in figure 2.1. 
Syk KD mice were then crossed with PF4-Cre expressing mice (generated as 
previously described). Syk K396R; PF4-Cre (SykK396R,fl,fl;PF4-Cre) mice were bred as 
heterozygotes to allow use of litter matched wild type controls. Syk K396R radiation 
chimeric mice were generated as previously described (136); briefly, foetal liver cells 
were isolated from Syk K396R embryos and transplanted via tail vein injection into 
irradiated wild type C57Bl/6 mice. Wild type C57Bl/6 mice were obtained from 
Harlan laboratories (Envigo, UK). For neonatal mice studies, wild type mice 
underwent timed-matings to allow exact gestational age determination. Mice were 
obtained and assessed from embryonic day (E)17.5 through to post-natal day 
(P)14.5.  
2.2 Methods 
2.2.1 Human Blood Collection and Platelet Preparation 
 
Blood from informed and consenting, drug-free adults was obtained on the day of 
experimentation by venepuncture into an anticoagulant solution of 10% (w/v) 
sodium citrate; once blood was obtained, 10% (w/v) acid citrate dextrose (ACD) was 
added to provide additional anticoagulation (ACD: 120mM sodium citrate, 110mM 
glucose, and 80mM citric acid). Consent complied with all local guidelines both in 
the UK and Chile and the guidelines set out in the Declaration of Helsinki. Washed 
platelets were obtained from whole blood samples via multiple centrifugation steps. 
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Firstly, whole blood was centrifuged for 20 minutes at 200g and 37°C to separate 
the platelet rich plasma (PRP) and platelet poor plasma (PPP); PRP was retained 
and PPP was discarded. PRP was then incubated with prostacyclin (10 µg/ml) to 
prevent unwanted platelet activation, before centrifugation for 10 minutes at 1000g 
and 37°C, causing deposition of a platelet pellet. Residual plasma was then 
discarded before the pellet was washed and resuspended in 3mls of ACD and 25mls 
of modified Tyrode’s solution (134mM NaCl, 2.9mM KCl, 0.34mM Na2HPO4, 12mM 
NaHCO3 1mM MgCl2, 5mM glucose, and 20mM HEPES; pH adjusted to 7.3). Once 
resuspended, prostacyclin (10 µg/ml) was again added before centrifugation was 
repeated for 10 mins at 1000g and 37°C. Platelet pellet was resuspended in 
modified Tyrode’s buffer at a concentration of 2x107 /ml for spreading analysis, 
2x108/ml for platelet aggregation assays and 4x107 – 1x109/ml for biochemical 
assays. Once resuspended, platelets were left for a minimum of 30 mins before 
experimental use to allow the effects of prostacyclin to wear off.  
2.2.2  Murine Blood Collection and Platelet Preparation  
 
Blood samples were obtained from mice via several different methods. For 
embryonic mice, pregnant females were culled at known gestational age via cervical 
dislocation and embryos were dissected out. Once isolated, embryos were 
decapitated and allowed to bleed into 10Units/ml of heparin in phosphate buffered 
saline (PBS). For post-natal juvenile mice and adult mice used as controls in the 
experiments exploring GPVI and CLEC-2 reactivity throughout development, mice 
were first culled via intraperitoneal (IP) injection of 50-100µl of Euthatal. Immediately 
~ 61 ~ 
 
following confirmation of death, mice were decapitated and allowed to bleed into 
10Units/ml heparin in PBS.  
 
For all other terminal adult mice experiments, initial administration of an 
isoflurane/oxygen mix (5% (v/v) isoflurane, ~1.5 l/min O2) was performed to 
anaesthetise the mouse prior to CO2 narcosis (CO2; 3-5 l/min). Once heartbeat 
cessation was observed, the peritoneum was opened, and the descending vena 
cava was isolated. Once isolated, the descending vena cava was punctured using 
a needle containing 100µl of ACD at 37°C and blood was withdrawn; once blood 
had been withdrawn, cervical dislocation was performed to confirm death. Blood 
was then diluted into 200µl of modified Tyrode’s buffer before centrifugation in a 
benchtop centrifuge for 5 mins at 200g and room temperature. Once spun, the PRP 
and top 1/3 of the red blood cell (RBC) fraction were transferred to a fresh Eppendorf 
and centrifuged again for 6 mins at 200g and 37°C. Once spun, the separated PRP 
was transferred to a separate Eppendorf and then another 200µl of modified 
Tyrode’s buffer was added to the remaining plasma and red blood cell mix, which 
was spun again for 6 mins at 200g and 37°C; this was performed to maximise the 
total platelet yield. Once this final spin was performed, the two sets of PRP were 
combined and spun in the presence of prostacyclin (10µg/ml) for 6 minutes at 1000g 
and 37°C to pellet the platelets. Platelet pellet was resuspended in modified 
Tyrode’s buffer at a concentration of 2x107 /ml for spreading analysis, 2x108/ml for 
platelet aggregation assays and 4x107 – 1x109/ml for biochemical assays. Once 
resuspended, platelets were left for a minimum of 30 mins before experimental use 
to allow the effects of prostacyclin to wear off.
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Figure 2.1 - Targeting strategy for generation of Syk K396R mice. A point mutation was introduced to induce an amino acid substitution 
in the kinase domain of Syk – the mutation resulted in a lysine to arginine substitution at site 396. The introduced allele was designed to 
allow expression of full length, wild-type Syk until mice were crossed with a Cre expressing mouse strain. Upon co-expression of the 
SykK396R,fl/fl transgene and a Cre – such as a PF4-Cre transgene – the Syk point-mutated protein is expressed. The point mutation in Syk 
induces a lysine to arginine substitution, maintaining the overall structure of Syk but rendering it catalytically inactive.  
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2.3 Platelet Function Assays 
2.3.1 Platelet Aggregometry  
 
All platelet aggregometry experiments were performed in a dual-channel Born lumi-
aggregometer (Model No. 460VS; Chronolog, Labmedics, Manchester, UK). 
Platelet aggregation was assessed in glass aggregometer cuvettes under stirring 
conditions (1200rpm) at 37°C; changes in optical density correlating to the 
magnitude of platelet aggregation were measured against a blank sample of 
modified Tyrode’s buffer. Platelets were added to the glass cuvettes and allowed to 
rest for at least 1 minute before being transferred to the heating chamber within the 
aggregometer for 1 minute and finally into the heated, stirring assay chamber for 1 
minute prior to the addition of any platelet stimuli. Changes in optical density were 
recorded on a manual chart recorder (Chronolog, Labmedics, Manchester, UK) for 
a minimum of five min post-stimulus addition. When the impact of platelet inhibitors 
or modulators of platelet aggregation was also being assessed, these inhibitors 
were allowed to incubate with the platelets inside the glass cuvettes for a minimum 
of 5 min prior to warming. 
 
2.3.2   Platelet Biochemical Sample Generation 
 
All platelet biochemical samples were generated in a dual-channel Born lumi-
aggregometer as described above. However, prior to the warming and stirring of the 
cuvettes, platelets were incubated with the αIIbβ3 inhibitor, Integrilin (also known as 
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eptifibatide; 9µM) to prevent platelet aggregation from occurring. Platelets were then 
rested, warmed and stirred as above before the addition of a platelet stimuli. 
Stimulation was allowed to continue for a set time period before reactions were 
terminated with the addition of either ice-cold lysis buffer (2x: 300mM NaCl, 20mM 
Tris, 2mM EGTA, 2mM EDTA, 2% (v/v) IGEPAL CA-630, pH 7.4, plus the addition 
on the day of experimentation of 5µg/ml leupeptin, 5µg/ml aprontinin, 0.5 µg/ml 
pepstatin, 2.5mM Na3VO4, and 100µg/ml AEBSF) or Laemmli sample buffer (2x 
non-reducing: 20% (v/v) glycerol, 4% (w/v) SDS, 50mM Tris, and Brilliant Blue R to 
required colour; 2x Reducing: 20% (v/v) glycerol, 4% (w/v) SDS, 50mM Tris, 10% 
(v/v) β-mercaptoethanol, and Brilliant Blue R to required colour); 5x Laemmli sample 
buffers were also used for some experiments and made up following the same 
proportions as for the 2x solutions above. Lysis buffer was utilised for samples 
undergoing subsequent immunoprecipitation steps, whereas Laemmli sample buffer 
was used for samples used for direct whole cell protein analysis. Immediately 
following cell lysis, samples were stored on ice before being transferred to -20°C 
storage prior to use.  
2.3.3   Platelet Spreading 
 
All platelet spreading experiments were performed on coated glass coverslips 
contained within 24 well cell culture plates. Prior to the platelet spreading 
experiment, glass coverslips were coated overnight at 4°C with one of the following 
platelet agonists: collagen (100µg/ml); fibrinogen (100µg/ml); fibrinogen + thrombin 
(100µg/ml; 30 mins + 1Unit/ml); or fibrin (100µg/ml fibrinogen; 30 mins + 1Unit/ml 
thrombin; 30 mins + 20µM PPACK to neutralise residual thrombin). Once coated, 
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residual agonist solution was removed before coverslips were washed three times 
with PBS. Non-specific binding sites were then blocked via the addition of 5mg/ml 
of heat-denatures bovine serum albumin (BSA) for 1 hour at room temperature. 
Following three more PBS washes, platelets were added to the glass coverslips and 
incubated at 37°C and allowed to spread for 30 mins (human) or 45 mins (mice); if 
inhibitors or modulators of platelet function were used, these were incubated with 
the platelet suspension for a minimum of 10 minutes prior to their addition to the 
coverslips. Following their incubation period, coverslips were again washed three 
times with PBS before being fixed by the addition of paraformaldehyde (PFA; 3.7% 
(w/v)) for 10 minutes. For fluorescent actin staining, coverslips were then washed 
again before platelets were permeabilised via the addition of 0.1% (v/v) Triton X-
100 for 5 minutes, followed by the addition of Alexa-488-phalloidin for 45 mins in the 
dark. Once stained, coverslips underwent a final wash step prior to mounting on 
glass microscope slides. Coverslips were imaged on a Zeiss Axiovert 200M 
microscope, and analysis of platelet spreading was performed using ImageJ 
(National Institutes of Health, Bethesda, MD); in each independent experiment, five 
images taken randomly throughout the coverslip were analysed (minimum 100 
platelets per condition per experiment.) 
 
2.3.4   Clot Retraction 
 
Clot retraction experiments were performed in isolated PRP. PRP was transferred 
into an Eppendorf and 5-10µl of RBCs were added back into the PRP to allow for 
better resolution of the developing clot. To begin the clot retraction experiment, PRP 
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+ RBC were incubated with 2mM CaCl2, 2mg/ml fibrinogen and 10Units/ml of 
thrombin. Images were taken at thirty-minute intervals for an hour and a half to 
document clot formation. Once clots had formed, they were washed in three 
changes of sodium cacodylate, fixed for 2 hours in 2% (w/v) glutaraldehyde, washed 
three more times in sodium cacodylate, and then dehydrated using increasing 
percentage acetone solutions in preparation for electron microscopy analysis. 
Electron microscopy was kindly performed by Robert Ariens from the University of 
Leeds. 
2.3.5   Flow Cytometry 
 
Flow cytometry was used to assess platelet surface receptor expression and platelet 
reactivity. All flow cytometry experiments were performed on a BD Accuri C6 flow 
cytometer (BD, Ann Arbor, Mi, USA). To assess platelet surface receptors, whole 
blood samples were diluted to give a concentration of ~10-20x109 platelets/L, before 
being dual stained for 30 mins under static, dark conditions at room temperature 
with an α-CD41*APC antibody – used to determine the platelet cell population – 
alongside a FITC conjugated antibody against the receptor of interest. After 30 mins 
reactions were terminated by the addition of a 4% (w/v) paraformaldehyde solution, 
followed by a 1/10 dilution of the sample with PBS. Once diluted, samples were then 
acquired on the flow cytometer. 
 
To assess platelet reactivity, whole blood samples were diluted to give a 
concentration of ~10-20x109 platelets/L, before being triple-stained with an α-
CD41*APC antibody, alongside an a-CD62*PE antibody and fibrinogen*Alexa 488. 
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Once antibodies and fluorescent fibrinogen had been mixed with the whole blood 
samples, this reaction mix was mixed 1:1 with 2x concentrated agonists and 
incubated at room temperature for 30 mins under static, dark conditions; PBS was 
used as a negative stimulation control in all reactivity experiments. After thirty 
minutes, reactions were terminated by the addition of a 4% (w/v) paraformaldehyde 
solution, followed by a 1/10 dilution of the sample with PBS. Once diluted, samples 
were then acquired on the flow cytometer. When run on the flow cytometer, 10,000 
platelet positive events were acquired and analysed for each sample; platelet 
positivity was determined via CD41+ staining alongside gating on cell size.  
2.4 Biochemical Analysis 
2.4.1   Immunoprecipitation  
 
Platelet lysates made using lysis buffer were defrosted before being pre-cleared by 
incubation with either Protein A or Protein G Sepharose beads (Pierce, Rockfield, 
IL) – dependent upon the species that the antibody of choice was raised in – under 
rolling conditions at 4°C for 1 hour; this was performed to reduce non-specific 
binding events in subsequent steps. After 1 hour, pre-clearing samples were spun 
in a benchtop centrifuge to pellet the beads and any non-specifically bound 
materials. Once pelleted, the supernatant was removed and transferred to a new 
Eppendorf, where the cleared supernatant was incubated with the specific antibody 
of choice and corresponding Sepharose beads at 4°C overnight with stirring. 
Following overnight incubation, samples were again spun to pellet the beads, before 
the remaining cleared supernatant was removed and stored for subsequent IP 
experiments. The pelleted beads were washed three times in lysis buffer, before 
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being eluted via addition of Laemmli sample buffer and subsequent boiling for 5 
minutes at 100°C. Once boiled, samples were analysed via SDS-PAGE and western 
blotting analysis.  
2.4.2   SDS-PAGE and Western Blotting Analysis 
 
Platelet lysates or immunoprecipitated samples in sample buffer were boiled for 5 
mins before being centrifuged at 8600g for 5 mins to pellet any insoluble cellular 
debris. Once centrifuged, samples were run on a pre-cast, gradient Bolt gel (4-12%) 
at 175V for 30-35 mins; alongside samples, a pre-stained molecular weight marker 
ladder was run to aid in determination of proteins of interest. Samples were 
separated via gel electrophoresis before samples were transferred from the gel to a 
polyvinylidene difluoride (PVDF) membrane using the trans-blot turbo electro-
transfer system. Once proteins were transferred, membranes were blocked for one 
hour at room temperature in 5% (w/v) BSA dissolved in Tris-buffered saline with 
tween (TBS-T; 200mM Tris, 1.37M NaCl, 0.2% (v/v) Tween20, pH 7.6); 0.1% (w/v) 
sodium azide was added to the 5% (w/v) BSA in TBS-T to prevent bacterial 
contamination. Once blocked, BSA was removed from the membranes, which were 
then incubated overnight at 4°C under mixing conditions with primary antibodies 
diluted in 5% (w/v) BSA in TBS-T.  
 
Once incubated overnight, membranes were washed three times for five minutes 
each in TBS-T. Once washed, membranes were then incubated with a secondary 
antibody specific to the species of the primary antibody, which was conjugated to a 
horseradish peroxidase enzyme; secondary antibodies were diluted in TBS-T and 
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membranes were incubated for 1 hour under mixing conditions at room temperature. 
After 1 hour, membranes were again washed three times for five minutes each in 
TBS-T, before being incubated with an enhanced chemiluminescence reagent 
(ECL, ThermoScientific, Paisley, UK) for a minimum of 1 minute before analysis. 
Membranes were either analysed via exposure to autoradiographic film or via the 
LiCor Odyssey-FC imaging system (LiCor, Cambridge, UK); autoradiographic film 
was used for generation of representative western blots and the LiCor system was 
used for protein band quantification. 
 
Once imaged, membranes were then stripped of antibody via incubation with a 
stripping buffer (TBS-T + 2% (w/v) SDS), to which 1% (v/v) β-mercaptoethanol was 
added, before being heated to 80°C for 20 mins. After 20 mins, membranes were 
rinsed in TBS-T briefly, before stripping buffer without β-mercaptoethanol was 
added and heated to 80°C for 20 mins. Once heated for a final 20 mins, membranes 
were rinsed repeatedly in TBS-T before being re-blocked in 5% (w/v) BSA in TBS-
T as above. Once blocked, the primary, secondary and ECL process was repeated 
utilising a loading control antibody, such as an antibody against βtubulin. 
2.5 Statistical Analysis 
 
All statistical analysis was performed using GraphPad Prism software (GraphPad, 
California, USA, various versions). Where graphically expressed, results are shown 
at arithmetic mean ± standard error of the mean, unless specifically stated 
otherwise. For parametric analysis, Student’s t-test was performed when comparing 
between two groups, and an ANOVA (one- or two-way) with appropriate post-hoc 
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multiple comparisons test was selected for experiments with three or more groups 
of comparison. For non-parametric analysis, a Mann-Whitney U-test was performed 
when comparing between two groups, and a Kruskall-Wallis test with appropriate 
post-hoc multiple comparisons test was selected for experiments with three or more 
groups. Statistical significance was assumed with p≤0.05.  
  






Characterisation of a novel Syk 
kinase-dead mouse model 




As discussed in the introduction to this thesis, Syk is one of the most important 
proteins within the (hem)ITAM signalling pathway. It has been shown numerous 
times that mice genetically modified to have a complete loss of the Syk protein – or 
expression of a dysfunctional form of the protein –  throughout all cell types display 
an embryonically lethal phenotype, possibly due to a failure of the lungs to inflate 
after birth (159, 229). These mice often display a number of severe physiological 
issues throughout development, such as defects in brain cerebrovasculture and 
lymphatic vascular formation (159, 161). It has also been shown that mice 
specifically lacking Syk, or again expressing a defective version of protein, 
specifically in the platelet/megakaryocytic cell lineage also display severe defects in 
the development of the brain and lymphatic vascular systems. Alongside the whole 
organism physiological defects, a dramatic impairment in the responses elicited 
following engagement of (hem)ITAM receptors on the platelet cell surface is also 
observed (136, 159). Interestingly, there is only a partial embryonic lethality 
phenotype observed in the platelet/megakaryocytic specific Syk deficient mice (136, 
159).  
 
Previous work from our group initially helped to identify that Syk was required for 
platelet (hem)ITAM function, and that it was platelets which appeared to be 
mediating the defects in lymphatic and brain vascular development – specifically via 
signalling through the CLEC-2 receptor (159). Building on these initial studies, work 
was recently undertaken to further explore the role that Syk and its regulation plays 
in platelet (hem)ITAM signalling and its functional consequences. Hughes et al fully 
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characterised a novel mouse model with a point mutation in the N-terminal SH2 
domain of Syk, an important regulatory domain required for recruitment of Syk to 
phosphorylated tyrosine residues contained within proteins at the plasma 
membrane (136). The results from this characterisation showed that, even though 
Syk could still function as a kinase, without recruitment to the membrane signal 
transduction was abolished through the (hem)ITAM pathways. This was the first 
time that translocation of Syk to the plasma membrane was shown to be required 
for (hem)ITAM mediated platelet signalling, and the data also suggests  that 
recruitment to the membrane appears to require functional forms of both SH2 
domains (136). 
 
Whilst the work discussed above has shown that the membrane localisation of Syk 
is integral for functional signal transduction – possibly due to its ability to act as a 
molecular scaffold following auto- and trans-phosphorylation events  (180) –  little 
work has been performed outside of cell lines to characterise how important the 
kinase domain of Syk is for signal transduction. It was hypothesised that the 
functionality of Syk may be mediated two-fold – via its kinase function and also via 
its adapter function – and that these two functions may be able to operate 
independently. To test this hypothesis, a novel mouse model was generated which 
carried a lysine-to-arginine substitution within the kinase domain of Syk (K396R), 
which has previously been shown to render kinases catalytically inactive due to the 
importance of this lysine residue in the phospho-transfer reaction; the Syk specific 
K396R mutation has also been used to study the effects of Syk kinase activity, 
mainly in cell lines (230-232). This mutant form of Syk was selectively expressed in 
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the platelet/megakaryocyte lineage and then the mice were fully characterised. The 
aims of this mouse model were to uncouple those effects of Syk mediated via its 
kinase function and those mediated by its adaptor capability. To further confirm that 
any functional differences in the Syk K396R mice were related to its adaptor 
function, Syk deficient (Syk-/-) chimeric mice were generated and assessed as a 
negative control.  
3.2 Results 
3.2.1 Generation of a conditional Syk kinase-dead mouse model 
(Syk K396R) 
 
Mice were generated by Taconic, using the targeting strategy shown in figure 2.1 
(Chapter 2), on a C57Bl/6 background. Once generated, SykK396R fl/fl mice were 
crossed with PF4-Cre expressing mice, also on a C57Bl/6 background. Mendelian 
breeding ratios for all breeding strategies are detailed in table 3.1. Briefly, SykK396R 
fl/fl;PF4-Cre+ mice did not breed to calculated Mendelian ratios, and showed a very high 
incidence of embryonic lethality; litter sizes were consequently much smaller than 
expected.  To counteract this, foetal liver cells were harvested from SykK396R fl/fl;PF4-
Cre+ embryos and these cells were infused into bone marrow ablated adult mice to 
generate radiation chimeras.  All subsequent assessments, unless otherwise stated, 
were conducted in the radiation chimeric mice.
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Table 3.1 – Mendelian breeding frequencies for all Sykk396R breeding strategies. SykK396R mice were bred using two main strategies: +/fl; PF4-Cre x +/fl; PF4-
Cre, and fl/fl x +/fl; PF4-Cre.Chi2 analysis was performed to determine any differences between expected and observed breeding frequencies, p≤0.005.  
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3.2.2 Syk K396R mice display developmental, lymphatic and 
haematological defects 
 
SykK396R fl/fl; PF4-Cre+ embryos assessed at embryonic day (E)16.5 displayed the 
hallmark phenotypes of mice deficient in Syk and/or CLEC-2 within the 
platelet/megakaryocytic lineage. Mice displayed significant haemorrhaging and 
blood spotting throughout the embryo alongside a large level of observable oedema, 
particularly surrounding the spine. The typical defects in lymphatic and blood 
vascular separation could also be seen in these embryos (figure 3.1a). In the 
irradiated mice infused with Syk K396R foetal liver cells, once the bone marrow was 
reconstituted mice began to display lymphatic defects. Chylous ascites was 
observable in these mice, alongside accumulation of red blood cells within both their 
mesenteric lymph vessels and lymph nodes (figure 3.1b). Mice also presented with 
raised, blood filled Peyer’s patches throughout their intestines (figure 3.1b); Peyer’s 
patches are secondary lymphatic organs involved in immune monitoring and are 
found throughout the ileum. Lastly, reconstituted mice displayed a significant drop 
in white and red blood cell counts (figure 3.1ci), a mild but significant increase in 
mean platelet volume (figure 3.3ci), and a significant change in immune system 
composition when compared with wild-type controls (figure 3.1cii). Interestingly, no 
changes in platelet count were observed between Syk K396R mice and wild-type 
controls (figure 3.1ci); red lines denote non-irradiated C57Bl/6 averages (233).  
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Figure 3.1 – Significant developmental, physiological and haematological defects are observed in Syk K396R 
embryos and irradiated/reconstituted chimeric adult mice. (a) Embryonic day (E) 16.5 mice were dissected 
and imaged; tail clippings were taken for genotyping (N≥3). (b) Adult SykK396Rfl/fl;PF4-Cre and Syk+/+;PF4-Cre 
radiation chimeric mice were dissected and images were taken of the peritoneum, axillary lymph nodes, 
mesenteric vasculature and Peyer’s patches; A = artery, V = vein, L = lymphatic vessel (N≥3). (c) White blood 
cell, red blood cell and platelet counts were assessed in whole blood samples, alongside mean platelet 
volume, using an ABX Pentra blood analyser (Horiba, Northampton, UK); white blood cell percentages were 
also measured; red lines denote non-irradiated C57Bl/6 averages (N=7). For blood counts, mean values are 
presented + standard deviation, differences were assessed using Student’s t-test. *p  ≤ 0.05, **p ≤ 0.01, *** p 
≤ 0.005, ****p ≤ 0.001 
(cii) 
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3.2.3 Syk K396R mice express (hem)ITAM receptors and 
signalling proteins at the same level as wild-type controls 
 
To ensure that all results observed were due to the loss of kinase activity of Syk, 
and not due to defects in (hem)ITAM receptor expression or trafficking, or in the 
expression of other key signalling molecules such as PLCγ2, receptor and signalling 
molecule expression profiles were assessed. Surface expression of GPVI, CLEC-2, 
GP1bα, α2bβ3 and α2β1 was not different between Syk K396R mice and wild-type 
controls (figure 3.2a). Similarly, the total cell expression levels of GPVI and CLEC-
2 were the same in Syk K396R mice as in wild-type controls. Expression of Syk, 
LAT and PLCγ2 proteins were also consistent between Syk K396R and wild-type 
control animals (figure 3.2b). Overall, no differences were observed in receptor 
expression – both total and at the cell surface – or the expression of a number of 
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Figure 3.2 – SykK396R chimeras display no differences in surface or total expression of key platelet 
receptors and signalling proteins. (a) Surface expression of GPVI, CLEC-2, GP1bα, αIIbβ3 and α2β1 was 
assessed via flow cytometry (N=3). (b) Total expression of PLCγ2, Syk, LAT, GPVI and CLEC-2 was 
assessed via western blotting (N=3).  For surface receptor expression analysis, data is presented as mean 
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3.2.4 Syk K396R mice display a significant impairment in 
(hem)ITAM – but not GPCR – signal transduction and 
responsiveness. 
 
Once receptor and protein expression was confirmed to be similar between wild-
type and Syk K396R mice, functional responses were assessed via lumi-
aggregometry, flow cytometry and biochemical analysis in wild-type (+/+; PF4-Cre), 
heterozygous Syk K396R (+/fl; PF4-Cre) and homozygous Syk K396R (fl/fl; PF4-
Cre). As measured by lumi-aggregometry, no differences were observed in 
response to 30µg/ml (figure 3.3ai) and 10µg/ml (figure 3.3aiv) collagen, 300nM 
(figure 3.3aii) and 100nM (figure 3.3av) rhodocytin or thrombin [0.1U/ml] (figure 
3.3aiii) between wild type and heterozygous Syk K396R platelets. However, 
differences in aggregation were seen in heterozygous mice at 3µg/ml collagen 
(figure 3.3avi) and 30nM rhodocytin (figure 3.3avii). Furthermore, in homozygous 
K396R mice no response was observed in response to collagen (figure 3.3ai) or 
rhodocytin (figure 3.3aii), but no difference was observed in response to thrombin 
(figure 3.3aiii).  Similar results were observed following flow cytometric analysis of 
platelet activation, as measured by both fibrinogen binding and P-selectin exposure. 
Wild-type platelets stimulated by increasing PAR-4 peptide, CRP or rhodocytin 
concentrations showed a typical dose response relationship for both fibrinogen 
binding and P-selectin exposure (figure 3.3bi-vi). However, homozygous Syk K396R 
mice showed no fibrinogen binding or P-selectin exposure in response to CRP 
(figure 3.3biii, 3.3biv) or rhodocytin (figure 3.3bv, 3.3bvi), but were indistinguishable 
from wild-types when stimulated with a PAR-4 peptide (figure 3.3bi, 3.3bii).  Wild-
type or homozygous K396R platelets were then stimulated with collagen [30µg/ml], 
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rhodocytin [300nM] or thrombin [0.1U/ml], and analysed via western blotting with a 
pan-phosphotyrosine antibody. Platelets from homozygous Syk K396R mice 
displayed a reduced level of phosphorylation of a protein ~72kDa and absent 
phosphorylation of proteins of ~135 kDa and ~32kDa in response to collagen and 
rhodocytin; these bands approximately correspond to the molecular weights of Syk, 
PLCγ2 and LAT, respectively (figure 3.3c). 
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Figure 3.3 – SykK396R fl/fl; PF4-Cre but not SykK396R +/fl; PF4-Cre mice display significant defects in aggregation, 
activation and intracellular signal transduction compared with SykK396R +/+; PF4-Cre controls. (a) 
Aggregation responses were measured in platelets from homozygous, heterozygous and wild-type 
chimeras, in response to several doses of collagen, rhodocytin and single doses of thrombin (N=3). (b) 
Platelet activation was measured via flow cytometry by assessing fibrinogen binding and P-selectin 
exposure in response to increasing doses of a PAR-4 peptide, CRP and rhodocytin; data is presented 
as mean ± SD and statistical analysis was performed via use of t-tests performed individually at each 
dose for each agonist, **p ≤ 0.01, ***p≤ 0.005, ****p≤ 0.001 (N≥5) (c) Pan-phosphotyrosine western 
blots of homozygous and wild-type SykK396R chimeras following stimulation with collagen, rhodocytin 
and thrombin (N=3).  
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3.2.5 A mild, partial potentiation effect is observed in Syk 
K396R and Syk KO platelets 
 
ADP synergises with other platelet agonists to induce powerful activation. Following 
the results observed for the homozygous Syk K396R mice, experiments were 
designed to test whether co-stimulation with ADP would synergise with collagen or 
rhodocytin to induce platelet activation. To test if this was the case, aggregations, 
flow cytometry activations and biochemical analysis were performed in wild-type 
(+/+; PF4-Cre), Syk K396R (fl/fl; PF4-Cre) and Syk KO (-/-) mice following co-
stimulations.  All mice displayed a minor shape change response when stimulated 
with ADP (figure 3.4ai), but neither Syk K396R or Syk KO mice underwent 
aggregation to collagen (figure 3.4aii) or rhodocytin (figure 3.4aiii); surprisingly there 
was a slow shape change response in Syk KO mice in response to both hemITAM 
agonists although this was not seen in all experiments. When co-stimulated with 
collagen and ADP, platelets from Syk K396R and Syk KO mice underwent weak 
aggregation (figure 3.4aiii). There was no change in response to ADP and 
rhodocytin in platelets from Syk K396R or Syk KO mice co-stimulated compared to 
rhodocytin alone (figure 3.4av). When assessed via flow cytometry by fibrinogen 
binding and P-selectin exposure, a small increase in fibrinogen binding was 
observed in Syk K396R platelets co-stimulated with CRP and ADP (figure 3.6bi, biii) 
or rhodocytin and ADP (figure 3.4bii, 3.4biv). A small increase was also observed in 
Syk KO mice, although there was a high level of variability in the responses for 
rhodocytin and ADP stimulation. Interestingly, when measure by P-selectin 
exposure, Syk K396R and Syk KO mice displayed no response irrespective of 
individual or co-stimulatory conditions (figure 3.4bii, 3.4biv). 
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Figure 3.4 – Platelets from SykK396R fl/fl; PF4-Cre and Syk-/- chimeras display significant defects in 
aggregation and platelet activation compared with wild-type chimeras following individual and 
co-stimulation with collagen and rhodocytin ± ADP. (a) Aggregation was assessed in platelets 
from SykK396R fl/fl; PF4-Cre, Sykfl/fl and wild-type chimeras following stimulation with collagen or 
rhodocytin ± ADP (N=3). (b) Platelet activation was measured via flow cytometry by assessing 
fibrinogen binding and P-selectin exposure in response to combinations of ADP, CRP and 
h d i  d  i  d     i  ( )   
(bi) (bii) 
(biii) (biv) 
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3.2.6 Phosphorylation of Syk, but not the downstream targets 
LAT or PLCγ2, is maintained in Syk K396R mice. 
 
Following the flow cytometry results, biochemical samples were generated and 
analysed via western blotting with both a pan-phosphotyrosine antibody (figure 3.5a) 
and a panel of phosphospecific antibodies against PLCγ2 (Y1217), Syk (Y525/526) 
and LAT (Y200) (figure 3.5b); these phosphospecific antibodies are all targeted 
against phosphotyrosine sites implicated in the activation state of their respective 
proteins. As seen in the previous western blotting experiments, when analysed 
using the pan-phosphotyrosine antibody a reduction in the level of phosphorylation 
of a band of around 72kDa and a complete loss of phosphorylation of proteins 
~135kDa and ~32kDa was observed in Syk K396R mice compared with wild-type 
controls, even when platelets were co-stimulated with hemITAM agonists and ADP 
(figure 3.5a). When probed with phosphospecific antibodies, these results were 
confirmed; Syk K396R mice displayed a reduction in Syk Y525/526 phosphorylation 
and a complete loss of PLCγ2 Y1217 and LAT Y200 phosphorylation, both when 
stimulated solely with collagen or rhodocytin and also when co-stimulated with ADP 
(figure 3.5b). However, a lack of loading controls prevents full quantitation of these 
experiments, and not knowing whether there is equal protein loading in each lane 
does confound the interpretation of these results.  
  




Figure 3.5 – Platelets from SykK396R fl/fl; PF4-Cre chimeras display a significant reduction in 
phosphorylation compared with wild-type chimeras following stimulation with collagen 
and rhodocytin ± ADP. (a) Pan phosphotyrosine western blots of platelets from SykK396R fl/fl; 
PF4-Cre and Syk+/+; PF4-Cre stimulated with collagen and rhodocytin ± ADP. (b) PLCγ2, Syk and 
LAT phosphospecific western blots of platelets from SykK396R fl/fl; PF4-Cre and Syk+/+; PF4-Cre 
stimulated with collagen and rhodocytin ± ADP (N=3).  
(a) 
(b) 
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3.2.7 Platelets from Syk K396R and Syk KO mice displayed a 
significant impairment in adhesion and spreading on a 
range of surfaces. 
 
An assessment of platelet spreading was undertaken in wild-type, Syk K396R and 
Syk KO mice to probe a more physiological read-out of platelet function. Platelets 
from all three genotypes were spread on collagen, fibrinogen and fibrin – fibrin was 
included due to the novel finding that fibrin can activate platelets through GPVI and 
associated ITAM signalling.  Representative pictures are contained in figure 3.6a, 
and full quantification of the spreading analysis is contained in figure 3.6bi-biii. As 
expected, spreading on collagen is significantly and largely impaired in Syk K396R 
and Syk KO mice compared to wild-type mice as measured by their area, perimeter 
and the total number of adherent platelets (figure 3.6bi). Surprisingly, when 
spreading on fibrin a larger impairment was observed in Syk K396R than in Syk KO 
mice compared with wild-type mice (figure 3.6bii). When spread on fibrinogen (figure 
3.6biii), no significant impairments were observed for any genotypes. 
 
  












Figure 3.6 – Platelets from SykK396R fl/fl; PF4-Cre and Syk-/- chimeras present with deficits in platelet 
spreading and adherence on collagen and fibrin, but not fibrinogen, coated surfaces compared with 
Syk+/+; PF4-Cre chimeras. (a)  Representative fluorescent images of platelets from Sykfl/fl; PF4-Cre, Sykfl/fl and 
Syk+/+; PF4-4Cre chimeric mice spread on collagen, fibrinogen and fibrin coated surfaces, 5µm scale bars. (b) 
Graphs showing the area, perimeter and number of adherent platelets from SykK396R fl/fl; PF4-Cre, Syk-/- and 
Syk+/+; PF4-Cre spread on collagen, fibrin and fibrinogen coated surfaces  Spreading of wild type (+/+; PF4-Cre), 
K396R (fl/fl; PF4-Cre) and Syk KO (-/-) platelets on collagen, fibrinogen and fibrin, data is presented as 
mean + SD and statistical analysis was performed using a one-way ANOVA with Tukey’s multiple 
comparisons post hoc test (N=3).  




The experiments performed in this chapter have focussed around the 
characterisation of a novel Syk kinase-dead mouse model, and any potential 
adaptor functions of the protein unrelated to kinase function.  
 
The breeding of the homozygous Syk K396R mice (SykK396R fl/fl; PF4-Cre) revealed an 
embryonically lethal phenotype, as confirmed via a subsequent Chi2 test on the 
mendelian breeding frequencies; this phenotype appears in-line with complete 
systemic ablation of Syk (Syk KO)(159). This result was unexpected, due to survival 
of the platelet specific Syk knock-out mice (Syk-/-; PF4-Cre mice), albeit this too is non-
Mendelian. It is likely that the expression of the dysfunctional protein is having an 
unknown and unexpected effect on cellular function, leading to an embryonically 
lethal phenotype. For example, complete loss of Syk may lead to the emergence of 
redundant pathways, which are not triggered when Syk is still expressed, albeit in a 
dysfunctional form; more work is required to determine the underlying cause of the 
embryonic lethality. It is also possible that, as shown in a recent paper by Calaminus 
et al (234), the PF4-Cre promoter is causing expression of the Syk K396R transgene 
in other myeloid and lymphoid cell types and inducing a worse phenotype; however 
the absence of a 100% embryonic lethality in the Syk-/-;PF4-Cre mice suggests this is 
unlikely to be the case (159). As with the Syk KO mice, one way around the 
embryonic lethality was the generation of radiation chimeric mice using foetal liver 
cells. All homozygous Syk K396R mice used in this chapter were radiation chimeras. 
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The first set of experiments performed were a series of physiological assessments 
of Syk K396R embryos (figure 3.1a) and also the adult Syk K396R chimeras (figure 
3.1b). These experiments showed that only the homozygous Syk K396R embryos 
displayed the phenotype typically associated with mice deficient in CLEC-2 or 
proteins involved in its signalling pathway (21, 158); homozygous Syk K396R 
embryos displayed severe blood spotting, haemorrhages, oedema and evidence of 
lymphatic vasculature dysfunction. When adult radiation chimeric mice were 
assessed following bone marrow reconstitution, they displayed blood filled 
lymphatic vessels and nodes, chylous ascites and raised Peyer’s patches as also 
seen in radiation chimeric mice reconstituted with CLEC-2-deficient bone marrow. 
This data suggests that a functional kinase domain is required for full signal 
transduction downstream of CLEC-2.  
 
Following the physiological assessment of the Syk K396R chimeric mice, full blood 
counts were performed, including an assessment of the proportions of each white 
blood cell type. Interestingly, no difference in platelet count and only a mild, but 
significant, increase in MPV was observed in Syk K396R mice. This data is not in 
agreement with the data from Hughes et al using the Syk R41A mice, although the 
mice used in their study were not radiation chimeras and displayed systemic 
lymphatic defects which were not observed in the chimeric mice (136); the more 
severe blood-lymphatic mixing phenotype in the native SykR41A;PF4-Cre mice is likely 
to result in a large circulating volume for platelets, leading to an apparent drop in 
platelet count. It was also interesting to note that there was a moderate, significant 
drop in red blood cell count and a large, significant drop in white blood cells – there 
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was also a significant difference in the composition of the leukocytes in the blood. 
Whilst the Syk K396R radiation chimeras were compared to irradiated and 
reconstituted wild-type controls, the complete bone marrow ablation and severe 
irradiation involved in the generation of these mice may affect these parameters, 
and they are not comparable to un-irradiated controls. 
 
Once the radiation chimeras had been generated, the first set of experiments 
performed were an assessment of the levels of surface receptor expression 
alongside total receptor and signalling protein expression. These experiments were 
performed to ensure that any results that were observed in the subsequent 
experiments were a direct result of the Syk K396R mutation, and not a result of 
differential receptor trafficking or protein expression. Results from these 
experiments (figure 3.2) showed no difference in surface or total expression of 
receptors, and similarly no difference in signalling protein expression, attributing all 
subsequent experimental results to the effects of the mutant form of Syk.  
 
Following on from the assessment of receptor and protein expression, a number of 
functional assays were performed on platelets from wild-type controls, heterozygous 
Syk K396R and homozygous Syk K396R mice. From these experiments it was seen 
that, in response to standard concentrations of collagen (30µg/ml) and rhodocytin 
(300nM), homozygous Syk K396R mice were completely unresponsive as 
measured by lumi-aggregometry (figure 3.3a). Interestingly, heterozygous Syk 
K396R mice displayed almost identical aggregation responses as wild-type mice, 
although some heterozygous mice did display a minor shift in dose response curve 
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at borderline inactive concentrations of collagen and rhodocytin (figure 3.3a). All 
three genotypes displayed indistinguishable responsiveness to the potent platelet 
agonist thrombin (figure 3.3a). Similar results were seen when platelet reactivity was 
assessed by flow cytometry in wild-type and radiation chimeric Syk K396R mice 
(figure 3.3b); radiation chimeric Syk K396R mice displayed no response to GPVI or 
CLEC-2 stimulation at any concentration but responded normally to an activating 
PAR-4 peptide. Syk K396R platelet samples were then stimulated with either 
collagen (30µg/ml) or rhodocytin (300nM) and taken for biochemistry. These 
samples showed reduced phosphorylation of a protein ~72kDa and absent 
phosphorylation of proteins ~135kDa and ~32kDa; as stated these molecular 
weights correspond roughly to the proteins Syk, PLCγ2 and LAT, respectively.  
 
Taken together, the above results highlight that without a functional kinase domain, 
Syk cannot support the transduction of the activatory signal generated following 
engagement of GPVI or CLEC-2 into a functional response – neither aggregation 
nor degranulation responses are present in Syk K396R platelets. Interestingly, 
whilst a level of phosphorylation is maintained on a protein likely to be Syk – most 
likely the result of trans-phosphorylation mediated via SFKs – the absence of any 
phosphorylation of proteins likely to be PLCγ2 or LAT suggests that the kinase 
function of Syk is indispensable to the signal transduction downstream of GPVI and 
CLEC-2, and any adaptor function cannot bypass this key signalling function of Syk. 
 
The fact that a level of phosphorylation was maintained on a ~72kDa protein likely 
to be Syk raised the possibility that co-stimulation of Syk K396R platelets may 
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overcome the signalling blockade induced via a lack of Syk kinase function. To 
assess this, platelets were co-stimulated with GPVI or CLEC-2 agonists in the 
presence and absence of ADP, a weak platelet agonist and mediator of ‘second-
wave’ platelet activation. Syk KO chimeras were generated as a negative control for 
these experiments to confirm if any agonist potentiation effects observed were 
mediated via an independent adaptor function of Syk. Also, phosphospecific 
antibodies against key phosphotyrosine sites in PLCγ2, Syk and LAT were used in 
these experiments to confirm the results suggested using the pan-phosphotyrosine 
antibodies. Experiments performed in the previous section of this chapter – lumi-
aggregometry, flow cytometry and western blotting – were repeated using wild-type, 
Syk K396R and Syk KO mice stimulated with hemITAM agonists alone or in 
combination with ADP. As per the previous results Syk K396R mice and, as 
expected, Syk KO mice did not undergo an aggregatory response to collagen or 
rhodocytin alone, whilst platelets from all three genotypes stimulated with ADP 
underwent a mild shape change response with no subsequent aggregatory 
response (figure 3.4).  
 
Interestingly, some of the Syk K396R and Syk KO mice underwent a small, irregular 
shape change response following hemITAM stimulation alone, however these 
responses were not reproducible and seemingly random, suggesting a possible 
mechanism unrelated to GPVI or CLEC-2 receptor signalling, such as activation of 
the Rho/ROCK signalling pathway (235). Surprisingly, when co-stimulated with 
ADP, collagen but not rhodocytin induced a mild but reproducible aggregatory 
response which was not present when the agonists were used individually; although 
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there are possible explanations such as a possible divergence within the GPVI and 
CLEC-2 signalling pathways, or differences in receptor clustering characteristics, 
more work is needed to clarify this discrepancy fully. However, this potentiation 
effect was observed in both the Syk K396R mice and the Syk KO mice which is 
suggestive of a completely Syk-independent mechanism of platelet activation being 
responsible for the potentiation effects, rather than the ability of Syk to act as an 
adaptor protein; indeed Syk-independent potentiation effects have previously been 
described downstream of GPVI in platelets (236).  
 
Flow cytometry stimulation experiments were repeated following co-stimulation. 
Surprisingly, Syk K396R platelets co-stimulated with CRP or rhodocytin and ADP 
did not appear to display the same level of potentiation as seen in the lumi-
aggregometry experiments; indeed, no statistically significant differences were 
observed in Syk K396R mice when individual stimulation with ADP or 
CRP/rhodocytin was compared with co-stimulation. One possibility for this is the 
difference in agonist for GPVI, as induction of platelet activation following collagen 
and CRP stimulations are slightly different, although there are several other 
possibilities and as above more work is needed to confirm the true cause of this 
disparity. However as seen in the lumi-aggregometry experiments, the magnitude 
of any potentiation effects was similar between Syk K396R and Syk KO platelets, 
again suggestive of a completely Syk-independent mechanism. It is also interesting 
to note that the P-selectin exposure responses are drastically reduced in the Syk 
K396R and Syk KO mice following individual and co-stimulations, whereas the 
impairment in fibrinogen binding is milder. This is suggestive of a particularly severe 
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defect in platelet degranulation in the Syk-impaired mice, which may also partially 
explain the lower levels of aggregation observed in the lumi-aggregometry 
experiments.  
 
Finally, biochemical analysis was performed using both pan-phosphotyrosine and 
phosphospecific antibodies following co-stimulation. Utilising the pan-
phosphotyrosine antibody, very similar results were observed as per the individual 
agonist stimulations performed previously. Whilst stimulation with ADP on its own 
induced no phosphorylation events in either wild-type of Syk K396R platelets, it 
appeared that co-stimulation of platelets with collagen/rhodocytin and ADP induced 
greater phosphorylation of proteins within the hemITAM signalling cascade, 
although in Syk K396R mice the phosphorylation of the ~135kDa and ~32kDa 
proteins was still absent. Phosphospecific antibodies against key tyrosine residues 
contained within PLCγ2 (Y1217), Syk (Y323, Y352, Y525/526) and LAT (Y200) were 
used to assess the phosphorylation patterns of these proteins, and confirm results 
seen when using the pan-phosphotyrosine antibody. Use of these phosphospecific 
antibodies was also of particular interest due to the possibly distinct functional roles 
of these phosphorylation sites, particularly within Syk, as discussed in depth in the 
general introduction of this thesis. The results of the phosphospecific analysis 
confirmed that phosphorylation was maintained at a reduced level within Syk at all 
tyrosine sites,and was mildly potentiated in samples from co-stimulated platelets 
whereas PLCγ2 and LAT phosphorylation was completely abolished in Syk K396R 
platelets. Remarkably, the two phospho-sites within Syk where phosphorylation was 
most strongly maintained in Syk K396R mice appear to be involved in increasing 
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Syk activity; Y525/526 residues are located in the kinase domain of Syk and are 
required for full Syk activity, whilst Y352 is thought to provide a docking site for 
positive regulators of Syk activity. However the loss of downstream signal 
transduction does question the importance of these observations when considering 
potentiation effects in the Syk K396R mice.  
 
The last set of experiments performed to characterise the Syk K396R mice were a 
set of platelet spreading assays. These assays were performed to explore platelet 
function in a slightly more physiological setting and to explore whether the activity 
of Syk K396R platelets differed when introduced to static agonists arranged on a 
surface. Both adherence and spreading of platelets on a collagen surface was 
significantly impaired in both Syk K396R and Syk KO mice when compared with 
wild-type controls, although surprisingly the severity of impairment seemed to be 
marginally higher in the Syk K396R mice compared with the Syk KO mice. Very 
similar results were observed when platelets were allowed to spread on a fibrin-
coated surface, however, the severity of impairment in response to fibrin appeared 
to be less than that observed in platelets spreading on collagen, and no difference 
in adherence was observed. These results are in keeping with the recent findings 
that fibrin can act as a GPVI agonist in platelets, although with less potency than 
collagen, and that defects in GPVI and its signalling pathway impair this response 
(140, 141, 237). Again, Syk K396R mice showed a more severe impairment in 
adherence and spreading on fibrin than Syk KO mice. Lastly, platelets were allowed 
to spread on fibrinogen, which has typically been thought to interact with platelets 
via the integrin αIIbβ3. No significant differences in platelet spreading were 
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observed when platelets were incubated on a fibrinogen surface; this data does not 
support the recent findings that fibrinogen – particularly when immobilised on a 
surface –  stimulates platelets through engagement of GPVI, however there is 
evidence that murine platelets are generally less sensitive to fibrinogen stimulation 
compared with human platelets  (237, 238). These results also suggest that Syk 
K396R mice have a more severe deficit in spreading response than Syk KO mice. 
This is surprising, as in most cases a complete loss of protein would be expected to 
induce a more severe phenotype than partial inactivation, however possibilities such 
as an inability to utilise complementary pathways without a complete absence of 
protein may explain these results. However, these hypotheses are currently purely 
speculative, and more experiments would be required to confirm or deny them.   
There are several limitations of the experiments performed within this chapter. 
Firstly, due to the embryonic lethality of this mutation, all functional experiments 
have been performed in reconstituted adult mice. Whilst the phenotypes are similar 
to those observed in other mouse strains with mutations in the GPVI and CLEC-2 
signalling pathways, this model is not fully comparable to models such as the R41A 
mice (136). As similar mutations, such as the Syk R41A mutation, do not display the 
same levels of embryonic lethality, crossing of the Syk K396R mice onto a different 
background or placing it under the control of a different platelet-specific promoter – 
such as the newly developed GP1bα-Cre (239) – would be useful to determine if it 
is the mutation or a genetic interaction causing the high lethality. Other 
methodological limitations include the omission of loading controls for the western 
blots performed in this chapter, preventing quantitation of these biochemical 
assessments and potentially confounding the assessment of any differences 
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between the different genotypes. Also, whilst average haematological parameter 
values have been included on the graphs in this chapter, these values are liable to 
differ between labs due to differences in areas such as blood collection techniques 
and blood analysis machines. For more comparable results, blood counts of stock, 
un-irradiated mice could have been obtained at the same time as the counts for the 
irradiated mice as comparators.  
 
Furthermore, whilst the functional tests performed in this chapter provide a good 
assessment of platelet reactivity, they are not true measures of in vivo haemostatic 
function, and so further assessments such as tail bleeding times or ferric 
chloride/laser injury models could be used in this model to assess the effects of this 
mutation on true haemostasis and thrombosis. Also, whilst co-stimulations have 
been used as a surrogate marker of Syk adapter function, experiments such as co-
immunoprecipitations and pull-down assays could be performed to determine which 
proteins still interact with the Syk K396R protein. Lastly, whilst ADP was selected 
as a co-stimulator of platelets due to its ability to induce a mild, reversible platelet 
aggregation (240) – essentially ‘priming’ the platelets for further stimulation via GPVI 
and CLEC-2 agonists – it would also be of interest to use other co-stimulatory 
agonists and secondary mediators of platelet activation to assess potential cross-
talk between the GPVI/CLEC-2 pathway and other platelet activation pathways.  
 
Overall, this chapter has focused on the characterisation of a novel platelet specific 
Syk kinase dead mutant mouse model. These mice, with a lysine to arginine 
substitution at location 396, displayed an embryonically lethal phenotype, which was 
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unexpected when considered next to other Syk-impaired or Syk-deficient models – 
some of this may be explained by the apparently more severe functional phenotype 
of Syk K396R mice compared with Syk KO controls. Syk K396R embryos and 
radiation chimeric mice present with a typical defective lymphatic phenotype 
associated with a loss of CLEC-2 expression or signalling and display a complete 
loss of aggregatory, activatory and secretory responses to hemITAM agonist 
stimulation; full reactivity following GPCR activation is maintained in Syk K396R 
mice. This loss of response to hemITAM stimulation is accompanied by a loss of 
phosphorylation of a number of key signalling proteins in the hemITAM signalling 
pathway. Although Syk K396R mice can undergo a partial recovery in reactivity to 
hemITAM agonists when co-stimulated with ADP, these potentiation responses 
were mirrored in Syk KO controls and were also not accompanied by any recovery 
of key protein phosphorylation. This is suggestive of a Syk-independent mechanism 
which is responsible for the potentiation responses seen in Syk K396R and Syk KO 
mice. The minor shape change responses sometimes seen in response to individual 
hemITAM agonist stimulation in Syk K396R mice were also seen at a similar rate in 
Syk KO mice, again suggestive of a Syk-independent mechanism controlling this 
shape change response. Phosphospecific biochemistry performed on these 
samples showed that whilst phosphorylation of Syk at several key regulatory sites 
was maintained in Syk K396R platelets under both individual and co-stimulation 
conditions, no phosphorylation was observed on key activatory tyrosine residues 
contained within PLCγ2 or LAT irrespective of stimulus.  Lastly, platelet adhesion 
and spreading on collagen, fibrin or fibrinogen was generally impaired in Syk K396R 
and Syk KO mice, although surprisingly the impairments were more severe under 
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all conditions in the Syk K396R mice. Taken together these results suggest that the 
kinase domain of Syk is integral to its function, and that whilst transphosphorylation 
events – likely mediated by SFKs – still occur on key regulatory and adaptor sites 
within Syk, these do not appear to be able to support signal transduction without a 
















Murine neonatal platelets are 
hypo-responsive to GPVI and 
CLEC-2 agonists 




It has long been known that there are significant functional differences between 
neonatal and adult platelets; humans are typically defined as neonates for the first 
28 days post-birth, irrespective of the length of gestation (241). Neonatal platelets, 
for example, have a defect in their responsiveness to many typical physiological 
platelet agonists such as collagen, ADP and thrombin (43, 242). What is also 
extremely interesting is that healthy neonates show no propensity to bleed, despite 
having defects in what have traditionally been seen as integral haemostatic 
pathways; some studies have even shown a mild increase in overall haemostatic 
capability (243, 244). Whilst some work has been performed in this area – aiming to 
understand the reasons why, despite presenting with often significant defects in 
platelet pathways that are extremely important in adult homeostasis, healthy 
neonates do not display any aberrant bleeding phenotypes – the molecular basis of 
these seemingly counterintuitive effects currently remains unknown.  
 
It appears that the maintained haemostatic capability of neonates is mediated 
heavily by the differences in the GP1bα-vWF pathway of platelet activation. It has 
been shown that there are much larger vWF multimers in foetal and neonatal 
plasma, likened to those seen in adult patients presenting with thrombotic 
thrombocytopenic purpura (TTP) (245) – TTP is a condition characterised by 
widespread thrombosis occurring in the microvasculature, associated with 
haemolytic anaemia and severe thrombocytopenia (246, 247) – as well as a 
reported upregulation of GP1bα expression on the platelet surface. When taken 
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together, this provides a possible explanation for the maintenance of haemostasis; 
upregulation of the GP1bα signalling pathway seems to compensate for the hypo-
reactivity of other pathways important in adult haemostasis. It is important to note, 
however, that there is still some controversy in the literature in this area, for example 
not all groups agree that neonates express higher levels of GP1bα compared with 
adults (248). 
 
Regarding the functional deficits present in both murine and human neonatal 
platelets, many different explanations have been proposed, often individualised for 
each signalling pathway. However, there remains a level of controversy surrounding 
several of these proposals. A lack of response to adrenaline in humans, for example, 
seems to be due to a widely accepted decrease in the number of receptors 
expressed by human neonatal platelets (249). There appears to be less agreement, 
however, for the basis of poor responsiveness to other agonists, such as collagen. 
A number of possible mechanisms have been investigated and it has been shown 
that processes such as calcium mobilisation (242, 250) and phospholipase activity 
(43) are impaired in human neonatal platelets when compared with adult platelets, 
suggesting the presence of signalling defects. A major issue with many of these 
studies however is their age; very little work has been undertaken recently either 
refuting or confirming and building upon the initial findings in these original studies. 
Also, much of the methodology of these studies is dated – for example, only small 
panels of receptors have been assayed for expression – likely due to availability of 
reagents and instruments at the time. This is further emphasised by the fact that, to 
date, only one paper using murine neonates appears to look at the functional 
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capability of the CLEC-2 signalling pathway, which shares a common set of 
signalling proteins with the collagen receptor, GPVI (45). Also, very few studies have 
explored (hem)ITAM and ITIM receptor expression as a potential mechanism for 
collagen hypo-responsiveness in neonatal platelets. 
 
One reason that it is particularly important to understand these functional differences 
between neonatal and adult platelets relates to the therapeutic options available for 
treating thrombocytopenia in neonates. The current treatment regime for neonatal 
thrombocytopenia is a platelet transfusion in conjunction with any appropriate 
treatment for the underlying cause, e.g. alloimmune thrombocytopenia, yet there 
does not appear to be any widely accepted and consistent guidelines for when and 
how neonatal platelet transfusion should be performed. Aside from the lack of clarity 
on neonatal platelet transfusion guidelines, no consideration is currently given to the 
aforementioned differences between neonatal and adult platelets. 
 
The aims of the experiments presented in this chapter are to generate an exact time 
course of platelet function, alongside a time course of platelet surface receptor 
expression throughout gestation. We wanted to first confirm that platelets have a 
poor responsiveness to collagen before assessing if this extended to CLEC-2 
agonists as well. Furthermore, we wanted to explore surface receptor expression as 
a potential mechanism for any lack of platelet response. There are some issues with 
the age stratification of neonates in a number of the studies; data is often not 
stratified via gestational ages but by birth weight and, although there does appear 
to be a correlation between birth weight and gestational age, this does not appear 
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to be absolute. We aimed to address this in the current study by using mice of 
precisely known gestational ages for platelet assessment, allowing us to build a 
much more detailed picture of the development of platelet function throughout 
development. Lastly, we utilised a model of platelet recovery after immune-
thrombocytopenia to 1) assess the maturity of newly formed platelets and determine 
if they revert to a developmental-like phenotype and 2) explore the possibility of 
increased platelet production pressure as a mechanism controlling differential 
composition and impaired reactivity of neonatal platelets when compared with 
adults. 
4.2 Results 
4.2.1 Platelet size remains constant from late gestation 
through to adulthood 
 
Platelet size was measured in all blood samples taken at all ages; size was 
assessed to determine whether any differences observed in subsequent receptor 
level assessments are due to differential expression or due to changes in platelet 
surface membrane surface area.  No significant differences in platelet size were 
observed from late gestation through to adulthood (figure 4.1), with an average MPV 























































Figure 4.1 – No differences were observed in mean platelet volume 
(MPV) of platelets from embryonic, neonatal and adult mice. Whole 
blood samples were obtained from embryonic, neonatal and adult 
mice and mean platelet volumes were measured via use of an ABX 
Pentra blood analyser (Horiba, Northampton, UK). Data is presented 
as mean + SEM, and statistical analysis was performed using a one-
way ANOVA (N≥6).  
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4.2.2 Neonatal platelets are hypo-reactive in response to GPVI 
and CLEC-2, but not PAR-4, stimulation 
 
Fluorescent fibrinogen binding (fibrinogen*Alexa 488) and P-selectin exposure 
(CD62p*PE) were measured in unstimulated platelets and platelets stimulated with 
increasing doses of GPVI, CLEC-2 or PAR-4 agonists. The gating strategy is 
outlined in figure 2, but briefly consisted of collecting 10,000 events that were CD41+ 
(CD41*APC) and within the FSC-SSC size parameters corresponding to platelets 
(figure 4.2a). Activation was then measured as the percentage of cells that were 
positive for either fibrinogen (figure 4.2bi) or P-selectin (figure 4.2bii) after 
stimulation as compared to cells incubated with PBS.  
 
Once appropriate gating strategies had been established, dose-response 
relationships were determined for collagen related peptide (CRP; GPVI), rhodocytin 
(CLEC-2) and an activatory PAR-4 peptide (PAR-4); CRP was chosen instead of 
collagen as it binds specifically to GPVI, allowing assessment of GPVI without 
activation of integrin α2β1, as would be the case with collagen. The dose-response 
results are detailed below in figure 4.3. As seen in figure 4.3ai, fibrinogen binding in 
response to CRP is significantly impaired in neonatal mouse platelets up to day ten 
when compared with adult mouse platelets at all concentrations. Interestingly, as 
seen in figure 4.3bi, fibrinogen binding in response to rhodocytin is also significantly 
reduced in neonatal mouse platelets at all ages, but the impairment appears to be 
most prominent at low and intermediate concentrations. PAR-4 induced fibrinogen 
binding was unaffected in neonatal platelets, as seen in figure 4.3ci, with no 
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significant differences at any developmental ages when compared with adult 
platelets.  
 
The exposure of P-selectin on the platelet surface following stimulation via GPVI, 
CLEC-2 and PAR-4 was also measured. Surprisingly, it was seen that P-selectin 
exposure was significantly reduced in response to all agonists at almost all 
gestational ages (figure 4.3). It also appeared that the pattern of response was very 















Figure 4.2 – Flow cytometry gating strategies used for determination of platelet populations and positive 
shifts denoting platelet activity; platelet populations were determined by CD41+ and FSC-SSC 
characteristics.  




Figure 4.3 – Embryonic and neonatal murine platelets are hyporeactive to CRP and Rhodocytin, but not a PAR-
4 peptide, up to day 14.5 post-birth. Platelet reactivity was assessed by fluorescent fibrinogen binding and P-
selectin exposure in embryonic and neonatal mice, measured via flow cytometry. Whole blood samples were 
stimulated with increasing doses of CRP (a), Rhodocytin (b) or a PAR-4 peptide (c). Statistical analysis was 
performed using a two-way ANOVA with a Dunnett’s multiple comparisons post hoc test comparing whole 
dose-response relationships, all groups were compared to adult dose-responses, ***p≤0.005, **** p≤0.001; 
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4.2.3 Platelet receptors are differentially expressed at the 
platelet surface throughout development 
 
The surface expression of a panel of receptors containing αIIbβ3, α2β1, GP1bα, 
PECAM-1, GPVI, and CLEC-2 was assessed. As seen in figure 4, all of the 
receptors were expressed at different levels throughout development, with only 
PECAM-1 reaching levels comparable with adult levels by days 10.5-14.5 post-birth 
(figure 4.4d). PECAM-1 was expressed at significantly higher levels in neonates 
compared with adults before returning to normal levels, whilst αIIbβ3 was initially 
expressed at higher levels during gestation, before dropping below adult levels by 
days 10-14.5 post-birth. Interestingly, GPVI and CLEC-2 levels were consistently 
significantly lower in neonatal mice than in adult mice, as were α2β1 and 
GP1bα levels. However, the actual differences in surface receptor expression 
appear to be relatively mild, with a maximum drop in GPVI of around 27% and a 
maximum drop in CLEC-2 of around 40%.  
 
  
   
 







* * * 
(b) 







* * * 
(f) 
Figure 4.4 – Embryonic and neonatal murine platelets express different levels of surface receptors compared 
to adult mice. Whole blood samples obtained from embryonic, neonatal and adult mice were stained for the 
platelet surface receptors αIIbβ3 (a), α2β1 (b), GP1bα (c), PECAM-1 (d), GPVI (e) and CLEC-2 (f), before being 
analysed via flow cytometry. Statistical analysis was performed using a one-way ANOVA with Dunnett’s 
multiple comparisons post-hoc test, *p≤0.05. Data is shown as mean ± SEM, N≥6 
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4.2.4 Murine platelets are hypo-reactive in response to GPVI 




Although it was discovered that neonatal platelets are hypo-reactive to GPVI and 
CLEC-2 agonists, and several possible mechanisms controlling this were explored, 
the overarching reasons underlying the need for this lack of GPVI and CLEC-2 
responsiveness remain to be elucidated. One hypothesis controlling this observed 
hypo-reactivity was that an increased stress on thrombopoietic mechanisms during 
periods requiring exponential platelet production – as would be observed during 
early development – may induce production of platelets from non-primary sites of 
thrombopoiesis and/or cause platelets to be released earlier in the thrombopoietic 
cycle to meet the increased demand. To model this situation, platelets generated in 
response to severe immune-induced thrombocytopenia were assessed for reactivity 
and composition. 
 
The responsiveness of newly formed platelets in mice that had experienced an 
immune-induced thrombocytopenia was assessed via flow cytometry following 
stimulation with CRP, rhodocytin and an activatory PAR-4 peptide (figure 4.5), as 
for the neonatal mice experiments above. An impairment in reactivity was seen in 
response to CRP when measured by both fibrinogen binding and P-selectin 
exposure in newly formed platelets from immune-depleted mice and this hypo-
reactivity was maintained up to days 7-9 post-depletion (figure 4.4a). A milder 
phenotype was seen in response to rhodocytin, where low to moderate doses of 
rhodocytin appeared to have less effect on the newly formed platelets, however this 
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impairment was no longer seen by days 4-5 post-depletion (figure 4.4b). PAR-4 
stimulation was unaffected in the newly formed platelets, displaying a very similar 
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4.2.5 Platelet receptors are differentially expressed at the 
platelet surface following platelet depletion  
 
The expression of platelet receptors on the cell surface was assessed via flow 
cytometry following immune depletion; The same panel of receptors (αIIbβ3, 
GP1bα, α2β1, PECAM-1, GPVI, and CLEC-2) were assessed in the newly formed 
platelets as those assessed in the neonatal platelets.  
 
Interestingly, in opposition to the results observed in the neonatal platelets, all of the 
platelet receptors – with the exception of GPVI and CLEC-2 – were expressed at a 
higher level on the surface of platelets formed following depletion (figure 4.6). It was 
particularly of interest that not all of the receptors returned to non-depletion levels 
after 7-9 days post-injection, and also that the receptor expressed most highly 
following depletion was the inhibitory receptor, PECAM-1. It was also surprising that 
the (hem)ITAM receptors were not expressed at different levels following immune-
induced thrombocytopenia.  





Figure 4.5 – Murine platelets are hyporeactive to CRP and Rhodocytin, but not a PAR-4 peptide, up to days 
7-9 following immune-induced thrombocytopenia. Platelet reactivity was assessed by fluorescent 
fibrinogen binding and P-selectin exposure in response to increasing concentrations of CRP (a), Rhodocytin 
(b) and a PAR-4 peptide (c), in mice recovering from immune-induced thrombocytopenia. Statistical 
analysis was performed using a two-way ANOVA with a Dunnett’s multiple comparisons post hoc test, 
*=p≤0.05. Data is shown as mean ± SEM, N≥6. 
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Figure 4.6 – Newly formed murine platelets express different levels of surface receptors following immune-depletion. Whole blood samples obtained from mice 
following immune-induced thrombocytopenia or IgG-injected controls were stained for the platelet surface receptors GP1bα (a), αIIbβ3 (b), α2β1 (c), PECAM-1 
(d), GPVI (e) and CLEC-2 (f), before being analysed via flow cytometry. Statistical analysis was performed using a one-way ANOVA with Dunnett’s multiple 
comparisons post-hoc test, *p≤0.05. Data is shown as mean ± SEM, N≥6. 
(a) (b) (c) 
(d) (e) (f) 
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4.2.6 Mean platelet volume is significantly increased following 
immune-depletion of platelets 
 
Mean platelet volume was assessed in newly formed platelets following immune-
depletion and compared with IgG injected controls. Size was again assessed to 
determine whether any differences observed in receptor levels are due to differential 
expression or due to changes in platelet surface membrane surface area. Following 
immune-depletion, a large increase in mean platelet volume was observed between 
days 2-3 and 4-5 post-depletion (figure 4.7); mean platelet volume appeared to 
normalise by days 7-9 post depletion. No significant differences were observed, 
however the variability of data was large and so a larger sample size may be 
needed.  
  




Figure 4.7 – Mean platelet volume is not significantly different following immune-induced 
thrombocytopenia. Mean platelet volume (MPV) was assessed in whole blood samples 
obtained following immune-induced thrombocytopenia or injection of control antibodies via 
use of an ABX Pentra blood analyser (Horiba, Northampton, UK). Data is shown as mean ± SEM, 
N≥6 
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4.3 Discussion  
 
This chapter has explored the reactivity of embryonic and neonatal platelets as 
compared with adult platelets, as well as some potential mechanisms controlling the 
observed differences. A model system, involving the depletion of platelets from wild-
type mice using a GP1bα antibody, was also used to try and recreate the conditions 
seen in developing murine platelets.  
 
Firstly, the experiments in this chapter have shown an impairment in the platelet 
response to GPVI stimulation in neonatal platelets and, further, have shown a similar 
level of impairment in response to the CLEC-2 agonist, rhodocytin. It was also seen 
that there was a very mild impairment in low-dose PAR-4 reactivity (figure 4.3). The 
reduced response to CLEC-2 stimulation is interesting, as CLEC-2 has been shown 
to be integral for lymphatic and cerbrovascular development (159, 161). However 
we can see that high dose rhodocytin appears to stimulate similar responses to 
those observed in adults, suggesting that high concentrations of CLEC-2 agonists 
may be able to overcome the mechanisms controlling platelet hyporeactivity in vivo, 
whilst GPVI agonists may not; however more work is needed to establish whether 
this is the case.  
 
Another interesting finding from the platelet activation studies was the finding that 
P-selectin exposure was significantly reduced in response to all agonists at most 
gestational ages (figure 4.3). It also appeared that the patterns of response were 
very similar, particularly in response to rhodocytin and an activating PAR-4 peptide. 
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Initially, this was thought to signal a defect in neonatal platelet granule secretion 
which was not present in the mecanisms controlling integrin activation. However, 
another possible explanation is that P-selectin protein levels are themselves 
developmentally regulated, and thus the differences observed were due to a 
combination of reduced platelet reactivity and a reduced pool of intracellular P-
selectin. Indeed, the developmental regulation of P-selectin has been described by 
others, such as the group of James Palis (251), many of whom have seen similar 
patterns of P-selectin exposure in response to platelet stimulation as those 
described in this chapter. Whilst this observation is undoubtedly interesting, it 
confounds the use of this protein as a marker of neonatal platelet reactivity.  
 
Once it was seen that the hypo-reactivity of platelets to GPVI agonists was 
replicable, experiments were performed to assess the differential expression of key 
signalling receptors on the platelet surface membrane as a potential mechanism. 
To explore this, the expression of several key platelet receptors on the surface 
membrane was assessed in embryonic and neontal platelets using flow cytometry. 
These results showed that, in general, the activatory receptors contained on the 
platelet surface are expressed at a lower level throughout embryogenesis and 
neonatal development when compared with adults (figure 4.4). It was interesting to 
note that, although the reduced receptor expression partially matches the time-
course of platelet hypo-reactivity, the reductions in platelet surface protein 
expression were generally mild, and thus unlikely to fully mediate the large 
impairment in platelet reactivity observed. When taken together, these results 
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suggest that their may be another common mechanism controlling the hypo-
reactivity seen to GPVI and CLEC-2 stimulation.  
 
It should also be noted that the ITIM receptor, PECAM-1, appears to be expressed 
at a significantly higher level in gestational and early neonatal platelets compared 
with adult platelets (figure 4.4). There is some evidence that increased PECAM-1 
signalling may impair collagen induced platelet activation (252). This proposes the 
distinct possibility that increased levels of PECAM-1 may be having an inhibitory 
effect on GPVI, and likely CLEC-2, induced signal transduction, leading to reduced 
platelet activity. More work would be required to definitively prove this as a 
mechanism however.  
 
It is also intriguing that integrin αIIbβ3 levels appear to be elevated in gestational 
and newborn mice compared with adults but drop steadily throughout early 
development and fall below adult levels between days 10.5-14.5 post-birth. This is 
interesting when we consider that neonatal platelet function appears, at least with 
respect to GPVI and CLEC-2 stimulation, to be inversely proportional to age. There 
are a number of potential explanations for this, such as the possibility that αIIbβ3 
levels are elevated as a compensatory mechanism for the poor responses elicited 
through other receptors, although from the dose-response assay (figure 4.3) the 
biggest impairment in fibrinogen binding occurs at the ages where the receptor 
levels are highest. This suggests that the elevated receptor levels do not appear to 
be compensatory and raises the possibility that there may be underlying issues with 
the activation of the integrin downstream of GPVI and CLEC-2 activation. This 
~ 130 ~ 
 
hypothesis seems to be in agreement with other previous data, where PAC-1 
staining of neonatal platelets was lower than that observed in adult platelets (253); 
PAC-1 is an antibody which binds to the active form of the αIIbβ3 integrin. 
 
Following the observations that embryonic and neonatal platelets were hyporeactive 
in response to (hem)ITAM agonists, and that the receptor expression profiles partly 
mirrored this, a model system was trialled to two ends: firstly, a model system would 
allow more in-depth analysis of potential mechanisms controlling platelet hypo-
reactivity in the longer-term, and secondly it could allow exploration of the 
overarching rationale for platelet hypo-reactivity throughout development. A model 
of high-stress platelet production was utilised to try and mirror the conditions present 
within the developing neonatal thrombopoietic system; mice were injected with a 
platelet depleting antibody and the reactivity and composition of the newly formed 
platelets were assessed. When reactivity was measured in these new platelets, a 
very similar phenotype to that present in the embryos and neonates was observed 
(figure 4.5); GPVI and, to a lesser extent, CLEC-2 reactivity was reduced in the 
newly formed platelets but no real effects on PAR-4 reactivity were observed. 
 
Following the identification of a similar platelet reactivity phenotype, assessment of 
platelet receptors was then undertaken. Suprisingly, the opposite results were seen 
in the newly formed platelets following immune-depletion compared with the 
neonatal experiments (figure 6). Platelets from mice that underwent immune-
depletion had much higher levels of all platelet receptors, with the exception of GPVI 
and CLEC-2  which were unchanged compared with non-depleted platelet controls. 
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However, a trend towards increased mean platelet volume was also seen in the 
platelets from mice undergoing depletion. This observation may suggests that due 
to a concurrent increase in platelet surface membrane area, the proportional 
changes in receptor expression would result in the only receptors with a different 
expression being GPVI and CLEC-2; this increase in platelet surface membrane 
would correspond to a decrease in the relative number of (hem)ITAM receptor 
molecules on the platelet surface. This decrease in the relative number of 
(hem)ITAM receptors on the platelet surface could partially account for the reduced 
response seen in these newly formed platelets. However, as previously seen, these 
differences are unlikely to fully account for the hyporeactivity in both the neonatal 
and platelet-depleted mice. The observation that the developing mice and the mice 
recovering from immune-depletion of platelets have similar phenotypes suggests 
that neonatal hypo-reactivity may be a byproduct of a high pressure, high volume 
thrombopoietic state, as seen in stages of exponential platelet production; it is also 
important to remember that neonatal platelets are produced in different locations 
than in adults, which may also impact their compositon and reactivity.  
 
This becomes even more interesting when considering work which has been 
performed recently, where adult platelets were infused into embryonic mice vessles 
and rapid, spontaneous thrombosis was observed (254). This result suggests that 
developing embryos, and particularly their blood vessels, may express a higher 
proportion of platelet activating molecules than typically found within adult vessels.. 
However, this field of research is in its infancy and so more work is required to 
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support either hypothesis, or potentially link them together throughout the complex 
stages of development.  
 
Further experiments that would be of interest would be to determine the expression 
levels and reactivity of a number of key signalling proteins in the (hem)ITAM 
signalling pathway, such as Syk, LAT and PLCγ2. Assessment of these proteins 
could help to determine if there is a common underlying signalling defect, which 
could act in conjunction with the reduced level of receptor expression to cause 
reduced platelet reactivity. Whilst work on the human arm of this study, performed 
by our collaborators in the group of Jose Rivera-Pozo, provides some evidence to 
suggest that this may be the case, more work is currently required – particularly in 
mice – and so this would be an area of particular interest (255). It would also be of 
interest to further utilise the platelet depletion model, as the greater blood volumes 
in adult mice treated with a platelet depleting antibody will allow for much more in-
depth assessments of platelet function, platelet biochemistry experiments – as per 
those described above – and even in vivo assessments of platelet function.  
 
There are a number of limitations of the experiments conducted within this chapter. 
Firstly, all of the experiments performed in this body of work have used inbred mice 
from the C57Bl/6 strain. Whilst the use of inbred mice is beneficial in some settings 
– such as the assessment of specific genetic mutations – it limits the generalisability 
of the results of these experiments; for example, it has been shown that the average 
baseline haematological parameters of different murine strains can vary 
significantly, potentially meaning that there may be issues such as different 
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pressures on thrombopoiesis in different strains (256). It would be of interest to 
repeat these experiments in either a different inbred mouse strain or in outbred mice 
to ensure that the developmental roles we have identified are consistent, and to 
generate more generalisable results. Furthermore, whilst the experiments here 
show some differences in the mean flourescent intensity of surface receptors, 
changes in these measurements do not necessarily correlate to absolute changes 
in receptor number. Therefore, it would be of interest to use tools such as flow 
cytometry kits allowing determination of absolute receptor counts, or western 
blotting for total protein levels if the issues surrounding minute blood volumes could 
be overcome. 
 
Overall, this chapter has replicated the hypo-reactivty of neonatal platelets to GPVI 
stimulation as previously shown, and expanded this to the signalling pathway-
sharing receptor CLEC-2. It has also shown that GPVI and CLEC-2 expression in 
developing mice is reduced, but not to an extent consistent with the strong 
impairment in reactivity. It has also shown a very similar pattern of reactivity in newly 
formed platelets following immune depletion, however the receptor expression 
results in this model are potentially ambiguous. Taken together, these results 
suggest that newly formed platelets are hypo-responsive to (hem)ITAM agonists, 
and that this hypo-reactivity may be a combined result of the location and high 










Platelets from patients deficient 
in GPVI do not respond to fibrin 
or fibrinogen 




As described in the general introduction to this thesis, it has recently been shown 
that fibrin can activate platelets through GPVI (140, 141). In this chapter, I extend 
this work to patients with a homozygous mutation resulting in loss of expression of 
GPVI on the platelet surface. A novel, homozygous mutation in the extracellular 
domain of GPVI was described in four unrelated families in Chile (257). This 
mutation introduces an adenine nucleotide into exon six of the GPVI gene, resulting 
in the generation of a premature stop codon prior to the membrane domain 
(c.711_712insA). This stop codon results in translation of a truncated form of the 
protein which is absent from the platelet surface. The four unrelated families were 
spread throughout the breadth of Chile but share a Spanish familial name, 
suggesting a possible founder mutation. Platelets from these patients do not 
respond to the typical GPVI agonists collagen, convulxin or CRP (257).  
 
In the present chapter, platelets from control, heterozygous GPVI c.711_712insA 
(GPVI+/-) and homozygous c.711_712insA (GPVI-/-) patients were assessed via 
aggregatory, spreading and biochemical analysis in response to collagen (positive 
control), fibrinogen (negative control) and fibrin. The GPVI+/- and GPVI-/- were from 
two separate families, both containing one heterozygote and one homozygote. This 
is the first time that platelets from patients with a congenital homozygous mutation 
in GPVI have been assessed for their responsiveness to the novel GPVI agonist, 
fibrin.  
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5.2 Results 
5.2.1 Platelets from GPVI-/- patients do not aggregate in 
suspension following stimulation with collagen or fibrin 
 
Platelet aggregometry was performed to measure the response to a homogenised 
suspension of cross-linked fibrin, fibrinogen, and collagen. The fibrin was made by 
incubating platelet poor plasma (PPP) with thrombin for 1 hour. Following formation 
and precipitation of the cross-linked fibrin mesh, the thrombin inhibitor PPACK was 
added to the fibrin suspension and mixed, before the fibrin-mesh precipitate was 
washed in PBS and sonicated on ice to form a homogenous solution of polymerised 
fibrin fibres.  
 
As seen in figure 5.1a, when stimulated with 30µg/ml collagen, platelets from a 
healthy control aggregated as expected and, interestingly, platelets from GPVI+/- 
patients aggregated almost normally, with only a very mild impairment in 
aggregation compared with controls. In contrast, platelets from GPVI-/- platelets 
displayed a complete lack of aggregatory response to collagen.  
 
When stimulated with the fibrin suspension (100µg/ml fibrinogen + 1 U/ml thrombin; 
figure 5.1b), platelets from a healthy control displayed a very strong aggregatory 
response, similar to that observed for healthy control platelets stimulated with 
collagen. Whilst platelets from GPVI+/- patients did respond to suspended fibrin, in 
contrast to the almost normal reactivity observed in response to collagen they 
displayed a marked reduction in aggregatory response compared to healthy control 
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platelets. Remarkably, platelets from GPVI-/- patients displayed no aggregatory 
response to the fibrin suspension.  
 
When 100µg/ml fibrinogen was added to the platelet suspensions, no aggregatory 
response was observed for any genotype. Reactivity was confirmed for all platelet 
preparations via stimulation with thrombin (figure 5.1c).  
 
For all of the aggregatory stimulations, lysates were prepared and analysed via 
western blotting following immunoprecipitation for Syk. Non-stimulation and 
fibrinogen stimulation did not induce Syk phosphorylation – a marker of GPVI 
pathway activation – in platelets from controls, GPVI+/- patients or GPVI-/- patients. 
Syk phosphorylation was observable in healthy control samples as expected, as 
well as in GPVI+/- patient samples. No phosphorylation was observable following 
collagen stimulation of GPVI-/- platelets. Unfortunately, due to the addition of BSA to 
the platelet preparations and the relative insolubility of the cross-linked fibrin fibres 
used in the stimulations, no assessment of the phosphorylation status of Syk – nor 

























Figure 5.1 – Platelets in suspension from GPVI-/-, but not GPVI+/- or GPVI+/+ patients, display a 
complete loss of response to collagen and fibrin, but not thrombin. Aggregation responses were 
measured in washed platelets obtained from GPVI-/-, GPVI+/- and GPVI+/+ patients in response to 
collagen (a), fibrin (b) and thrombin (c) (GPVI-/-, N=2; GPVI+/-, N=2; GPVI+/+, N=1). Phosphorylation 
of Syk was measured in platelets obtained from GPVI-/-, GPVI+/- and GPVI+/+ patients, and 
stimulated with collagen, fibrin and fibrinogen, via immunoprecipitation and subsequent pan-
phosphotyrosine staining, figure is representative of N=2 (GPVI-/-, GPVI+/-) and N=1 (GPVI+/+).  
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5.2.2 Platelets from GPVI-/- patients display impaired spreading 
on collagen coated surfaces 
  
Platelet spreading on collagen was assessed in this study as it is the prototypical, 
physiological agonist for GPVI, and also acts a positive control for loss of function. 
Following incubation of untreated platelets from GPVI+/-, GPVI-/- and control platelets 
on a collagen coated surface, a numerical reduction in the number of spread 
platelets and spread platelet surface area was observed in platelets from GPVI-/- 
patients when compared with control platelets, whilst untreated GPVI+/- platelets 
were indistinguishable from controls (figure 5.2).  
 
Platelets were then pre-incubated with the αIIbβ3 inhibitor integrilin to isolate any 
GPVI specific spreading defects; αIIbβ3 is the most highly expressed platelet 
integrin and has been shown to play a key role in platelet spreading. When platelets 
were pre-incubated with integrilin and spread on collagen (figure 5.2), a marked 
reduction in spread platelet area was observed for all genotypes compared with 
untreated platelets. Interestingly, when the level of platelet adherence was assessed 
under these conditions, a numerical difference was observed in GPVI-/- samples 
compared with controls as expected, however less adherence was also observed in 
the GPVI+/- platelets from the patient in family 1 but not family 2.  
 
Platelets were also pre-treated with the SFK inhibitor PP2, to ensure that tyrosine 
kinase signal transduction, and GPVI function, was completely inhibited in these 
samples, and also to determine if any spreading responses might be due to fibrin 
interacting with any of the other hemITAM receptors expressed on human platelets. 
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When platelets were pre-incubated PP2 and spread on collagen (figure 5.2), there 
was a mild reduction in spread area for all genotypes compared with untreated 
samples, however the largest differences again remained between GPVI-/- patients 
and controls (figure 5.2). Interestingly, in terms of platelet adherence to a collagen 
surface, PP2 induced similar changes to those observed in platelet preparations 
pre-treated with integrilin, with the largest differences observed between both GPVI-
/- patients, alongside the GPVI+/- patient from family 1, and controls (figure 5.2). 
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 (a) 








Figure 5.2 – Platelets from GPVI-/- and, to a lesser extent GPVI+/-, patients display impaired 
spreading on collagen coated surfaces compared with a GPVI+/+ control. (a) Representative 
microscopy figures of platelets in the presence and absence of PP2 and integrilin, obtained from 
GPVI-/-, GPVI+/- and GPVI+/+ subjects, when spread on collagen coated surfaces, scale bar = 5µM. (b) 
Quantitation of spread platelet area, perimeter and number of adherent platelets obtained from 
GPVI-/-, GPVI+/- and GPVI+/+ patients, in the presence and absence of PP2 and integrilin, when 
spread on collagen coated surfaces (GPVI-/-, GPVI+/-, N=2; GPVI+/+, N=1). 
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5.2.3 Platelets from GPVI-/- patients display impaired spreading 
on CRP coated surfaces 
 
Platelet spreading on CRP was assessed in this study as whilst it is similar to 
collagen, it activates GPVI in the absence of concurrent stimulation of the integrin 
α2β1; collagen induces activation of both receptors. The use of CRP allows for direct 
assessment of the impact of loss of GPVI on functional responses. Following 
incubation of untreated platelets from GPVI+/-, GPVI-/- and control platelets, a large  
reduction in spread platelet surface area was observed in platelets from GPVI-/- 
patients when spread on CRP (figure 5.3); surprisingly, the GPVI-/- patient from 
family 1 displayed a larger impairment in platelet adherence on CRP than the GPVI-
/- patient from family 2 (figure 5.3). Untreated GPVI+/- platelets were indistinguishable 
from controls in all readouts of platelet spreading (figure 5.3).  
 
When pre-treated with integrilin, a global reduction in spread area compared with 
untreated samples was observed in response to CRP – similar to that seen for 
collagen. However, a surprising difference was observed in the GPVI+/- patient from 
family 2, alongside the expected differences in the GPVI-/- patients (figure 5.3) when 
compared with controls. As expected, GPVI-/- patients displayed a large reduction in 
platelet adherence compared to controls following integrilin pre-treatment (figure 
5.3).  
 
When platelets were pre-treated with PP2, a reduction in spread platelet area was 
observed in all genotypes – similar to that observed for PP2-treated samples spread 
on collagen – compared with untreated platelets; the GPVI-/- patients again 
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displayed the largest differences in spreading compared with controls (figure 5.3). 
Interestingly, when the number of adherent platelets was assessed, both GPVI-/- 
patients as well as the GPVI+/- patient from family 1 showed similar reductions 
compared to controls (figure 5.3).  











Figure 5.3 – Platelets from GPVI-/- and, to a lesser extent GPVI+/-, patients display impaired 
spreading on CRP coated surfaces compared with a GPVI+/+ control. (a) Representative 
microscopy figures of platelets in the presence and absence of PP2 and integrilin, obtained from 
GPVI-/-, GPVI+/- and GPVI+/+ subjects, when spread on CRP coated surfaces, scale bar = 5µM. (b) 
Quantitation of spread platelet area, perimeter and number of adherent platelets obtained from 
GPVI-/-, GPVI+/- and GPVI+/+ patients, in the presence and absence of PP2 and integrilin, when 
spread on CRP coated surfaces (GPVI-/-, GPVI+/-, N=2; GPVI+/+, N=1). 
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5.2.4 Platelets from GPVI-/- patients display impaired spreading 
on fibrinogen coated surfaces 
 
Platelet spreading on fibrinogen was assessed in this study as a control, as it was 
not believed that fibrinogen interacts with GPVI to induce platelet spreading. 
Following incubation of untreated platelets from GPVI+/-, GPVI-/- and control 
platelets, an entirely unexpected reduction in the number of adherent platelets and 
the spread platelet surface area was observed in platelets from GPVI-/- patients 
when spread on fibrinogen (figure 5.4). Again, untreated GPVI+/- platelets were 
indistinguishable from controls in all readouts of platelet spreading (figure 5.4).  
 
When pre-treated with integrilin a large reduction in platelet surface area was 
observed for all GPVI+/- and GPVI-/- patient samples compared with controls (figure 
5.4); integrilin appeared to have little effect on the control samples compared to 
untreated control platelet samples. Interestingly, integrilin pre-treatment induced the 
largest reduction in platelet adherence on fibrinogen in GPVI patients from family 1; 
both GPVI+/- and GPVI-/- patients from family 2 displayed much smaller differences 
in adherence compared (figure 5.4).  
 
When pre-treated with PP2, no real differences in platelet spreading in GPVI+/- 
patients were observed compared with untreated samples; both GPVI-/- patients 
again displayed large reductions in platelet surface area compared with controls 
(figure 5.4). However, another extremely surprising result was observed in platelet 
adherence, as PP2 pre-treatment appears to potentiate the adherence of all patient 
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samples to a fibrinogen surface; the GPVI+/- patient from family 2 displayed an 
increase in platelet adherence compared with controls (figure 5.4).  
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(a) 







Figure 5.4 - Platelets from GPVI-/- and, to a lesser extent GPVI+/-, patients display impaired 
spreading on fibrinogen coated surfaces compared with a GPVI+/+ control. (a) Representative 
microscopy figures of platelets in the presence and absence of PP2 and integrilin, obtained from 
GPVI-/-, GPVI+/- and GPVI+/+ subjects, when spread on fibrinogen coated surfaces, scale bar = 
5µM. (b) Quantitation of spread platelet area, perimeter and number of adherent platelets 
obtained from GPVI-/-, GPVI+/- and GPVI+/+ patients, in the presence and absence of PP2 and 
integrilin, when spread on fibrinogen coated surfaces (GPVI-/-, GPVI+/-, N=2; GPVI+/+, N=1). 
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5.2.5 Platelets from GPVI-/- patients display impaired spreading 
on fibrin coated surfaces 
 
Platelet spreading on fibrin was assessed in this study as it was recently described 
to be a novel agonist for GPVI. Following incubation of untreated platelets from 
GPVI+/-, GPVI-/- and control platelets, a large reduction in spread platelet surface 
area was observed in platelets from GPVI-/- patients when spread on fibrin (figure 
5.5). Interestingly, impairments in platelet adherence were observed in both GPVI-/- 
patients, alongside the GPVI+/- patient from family 1; the GPVI+/- patient from family 
2 was much more similar to controls (figure 5.5). Untreated GPVI+/- platelets were 
indistinguishable from controls when measured via platelet surface area (figure 5.5).  
 
When pre-treated with integrilin, whilst a reduction in platelet surface area was 
observed for all genotypes, the largest impairments were observed in the GPVI+/- 
patient from family 1; surprisingly smaller differences were observed in GPVI-/- 
patients compared with the heterozygous patient from family 1 (figure 5.5). When 
platelet adherence was assessed, both GPVI-/- patients displayed a substantial 
impairment compared with controls, as did the GPVI+/- patient from family 1 (figure 
5.5).   
 
When pre-treated with PP2, again a mild difference in platelet spreading was 
observed compared with untreated samples for all genotypes; again the GPVI-/- 
patients displayed the largest reduction in platelet surface area compared with 
controls (figure 5.5). However, PP2 pre-treatment again appears to potentiate the 
adherence of patient samples to a fibrin coated surface; the GPVI+/- patient from 
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family 2 again displayed an increase in platelet adherence compared with controls 
(figure 5.5).  
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 (a) 






Figure 5.5 - Platelets from GPVI-/- and, to a lesser extent GPVI+/-, patients display impaired 
spreading on fibrin coated surfaces compared with a GPVI+/+ control. (a) Representative 
microscopy figures of platelets in the presence and absence of PP2 and integrilin, obtained from 
GPVI-/-, GPVI+/- and GPVI+/+ subjects, when spread on fibrin coated surfaces, scale bar = 5µM. (b) 
Quantitation of spread platelet area, perimeter and number of adherent platelets obtained from 
GPVI-/-, GPVI+/- and GPVI+/+ patients, in the presence and absence of PP2 and integrilin, when 
spread on fibrin coated surfaces (GPVI-/-, GPVI+/-, N=2; GPVI+/+, N=1). 
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5.2.6 There appear to be no differences in the kinetics of 
thrombus formation between GPVI-/-, GPVI+/- and controls. 
 
One of the key roles of fibrin is in the stabilisation and retraction of thrombi, and so 
it was hypothesised that patients deficient in GPVI may have impaired functional 
responses due to diminished fibrin signal transduction. To assess this, a modified 
clot retraction assay was performed, and the time-course of clot formation was 
measured.  
 
As can be seen from the temporal analysis of thrombus formation (figure 5.6), 
thrombi formed over equal timescales regardless of genotype, and gross thrombi 
morphology was broadly similar across genotypes and timepoints (figure 5.6). 
Analysis of the kinetics of thrombus formation was performed visually, and as such 
further clot retraction experiments should be performed to assess the kinetics in 
more detail. 
 




























Figure 5.6 – GPVI-/- and GPVI+/- patients display no visual differences in the kinetics of 
thrombus formation compared with a GPVI+/+ control. Platelet rich plasma was obtained 
from GPVI-/-, GPVI+/- and GPVI+/+ subjects and a small volume of red blood cells was re-
introduced, before CaCl2, fibrinogen and thrombin were added. Pictures were taken every 
30 mins and after 60 mins, clots were dehydrated and fixed in glutaraldehyde for scanning 
electron microscopy analysis, N=3.  
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5.2.7 There appear to be no differences in the macro- or 
microscopic thrombus ultrastructure between GPVI-/-, 
GPVI+/- and controls. 
 
Following the modified clot retraction assay, clots were fixed, dehydrated and 
assessed via scanning electron microscopy (SEM). Following sixty minutes of clot 
retraction, samples were fixed and dehydrated before scanning electron microscopy 
analysis; scanning electron microscopy was kindly performed by Professor Robert 
Ariens. As can be seen from all of the different SEM magnifications – 5000x (figure 
5.3bi), 10000x (figure 5.3bii), 250000x (figure 5.3biii), and 50000x (figure 5.3biv) – 
there appear to be no differences in thrombi structure. The fibrin fibre size, density, 
organisation and locations all appear to be similar across all genotypes, and no 
differences are apparent in the presence/absence of cells including platelets, red 
blood cells and/or white blood cells. 
 
All analysis of the SEM pictures was performed visually, and further, more in-depth 
analysis of this data is required to elucidate any minor differences in thrombus 
structure that may exist. 
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Figure 5.7 – Thrombus composition appears similar between GPVI-/-, GPVI+/- and GPVI+/+ patients. Scanning electron microscopy (SEM) images at 5000x 
(a), 10000x (b), 25000x (c) and 50000x (d) magnification. SEM was kindly performed by Professor Robert Ariens, and data was assessed visually (N=1 for 


















This chapter has shown for the first time that patients with a homozygous mutation 
in GPVI rendering it absent from the platelet surface membrane do not respond to 
fibrin stimulation in suspension or on a surface and is the first description of a 
requirement for GPVI on the surface of human platelets to support spreading on 
immobilised fibrinogen.  
 
When measures specific to platelet activation and function were assessed, namely 
platelet aggregometry and spreading, patients with a homozygous GPVI mutation 
displayed a complete loss of response to the typical GPVI agonists collagen and 
CRP; these results are in keeping with previous models of GPVI abrogation, such 
as knock-out mouse models (258). Surprisingly however, family members with a 
heterozygous expression pattern of the GPVI mutation were almost 
indistinguishable from healthy controls, particularly in response to collagen (figure 
5.1 and figure 5.2). This is particularly surprising, as the heterozygous GPVI patients 
have previously been described to have an intermediate reduction in GPVI surface 
expression, and heterozygous GPVI knock-out mice appear to have an intermediate 
reduction in response to agonists such as collagen (257, 258). These results 
suggest that there may be a ‘critical mass’ of GPVI molecules required on the 
surface of a platelet to support activation and signal transduction; however, it would 
be important in the first instance to complete full dose-response profiles for the 
heterozygous patients to several GPVI agonists – similarly to studies in mouse 
models – to determine whether a mild reactivity defect at borderline stimulatory 
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concentrations exists. It would remain interesting, however, to determine if there is 
a ‘magic number’ of GPVI molecules, as whilst these patients are the only described 
patients with a homozygous mutation resulting in loss of GPVI, there are several 
other more common conditions which might induce a reduction or complete abolition 
of GPVI expression at the platelet surface. Conditions such as immune 
thrombocytopenic purpura and systemic lupus erythematosus have been 
associated with a loss of platelet GPVI expression (259) and understanding the 
critical level of GPVI expression may aid in the future management of these, and 
similar, conditions.  
 
As discussed, there is a complete loss of aggregatory response to both the typical 
GPVI agonists and fibrin in the homozygous GPVI patients (figure 5.1). Interestingly, 
when platelets were assessed via spreading analysis, there was a substantial 
reduction in platelet spreading on fibrin, however platelet adherence – as measured 
by the number of platelets per field of view – was not as strongly affected (figure 
5.5). Whilst the differences in platelet spreading have been observed previously 
(140), albeit in mouse models, differences in adherence have previously only been 
measured via methods such as platelet flow over fibrin coated surfaces; this analysis 
displays significant defects in platelet adherence to fibrin both in GPVI knock-out 
mice and human GPVI-depleted platelets (141). One obvious difference between 
these two protocols is that one is a static assay whilst one has the presence of 
platelet flow, making it likely more physiological, however a comparison of the two 
methods may provide valuable information on potential differences in the 
importance of the GPVI-fibrin adherence interaction in high pressure, high flow 
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vessels, such as arteries, and low pressure, low flow vessels, such as veins.  Whilst 
no such discrepancy is observed in platelet spread on agonists such as collagen 
(figure 5.2), this disparity in the response to fibrin in this study may possibly be 
explained by the presence of the traditional platelet fibrin receptor, integrin αIIbβ3. 
Indeed, there is a large drop in the number of adherent platelets observed for all 
genotypes and agonists when platelets pre-treated with the integrin αIIbβ3 inhibitor 
integrilin are compared with untreated platelets (figures 5.2-5.5). Taken together, 
this information suggests that both GPVI and αIIbβ3 are important for the response 
of platelets to fibrin, but that the receptors may play different roles and be important 
at different times; indeed the spreading analysis seems to suggest that GPVI 
appears to be important for the both the activation and spreading of platelets in 
response to fibrin, whereas αIIbβ3 appears to be important for tethering,  adherence, 
also the spreading of platelets. It is also interesting that the patients from family 1 
appear to be more severely affected in the spreading experiments, particularly when 
platelets are pre-incubated with inhibitors of platelet function. For example, the 
GPVI+/- patient from family 1 often displays impairments in line with the GPVI-/- 
patients, following pre-treatment with inhibitors. It would be interesting to assess this 
family for other underlying mutations which may affect platelet function, as well as 
comparing the surface expression levels of GPVI between the two families. 
 
Perhaps one of the more surprising results from previous research into GPVI using 
deficient mouse models is the minor physiological bleeding phenotypes observed; 
similar mild bleeding diatheses have been observed in the compound heterozygous 
and homozygous GPVI patients (141, 257, 258). When considering the textbook 
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descriptions of platelet activation and thrombus formation, and the integral roles that 
collagen (initial platelet tethering and activation at sites of vascular damage) and 
fibrin (fibrin mesh formation and clot retraction) have been recorded as playing 
(260), it is surprising that a loss of GPVI does not induce a catastrophic loss of 
haemostatic capability. However, when a modified clot retraction assay was 
performed in both healthy controls, GPVI+/- patients and GPVI-/- patients (figures 5.6-
5.7), there appeared to be no differences in the rate of thrombus formation (figure 
5.6) nor in the observable macroscopic and microscopic thrombus components and 
composition (figure 5.7); for example, the fibrin fibres and presence of red and white 
blood cells appeared comparable between all genotypes. However, the analysis of 
this data has been performed visually, and as such is not particularly robust; more 
in-depth analysis of these experiments is required to elucidate the full profiles of 
GPVI+/- and GPVI-/- samples compared to controls. Further analysis of the dynamics 
of thrombus formation and retraction in these patients would also be interesting 
when considering the results of previous studies, which have shown a loss of GPVI 
mediates an often significant defect in thrombus stability (140, 141). 
 
This data does suggest, however, that whilst GPVI may be important in platelet 
activation and thrombus formation, there are other redundant systems in place 
which can contribute to both initial platelet tethering and activation – systems such 
as the VWF-GP1ba signalling axis (261) – alongside the mediation of platelet-fibrin 
interactions – receptors such as αIIbβ3 (262). Coupled with the importance of fibrin 
in the coagulation cascade (65) – a complementary mechanism of haemostasis – 
alongside the release of agonists such as thrombin and ADP from activated platelets 
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and expression of potent pro-coagulant proteins such as tissue factor on damaged 
endothelial cells, it appears that the importance of GPVI in maintaining haemostasis 
may be overcome by other complementary systems in vivo.  
 
Another interesting and unexpected result from these experiments was the defect 
in platelet adherence and spreading on fibrinogen in homozygous GPVI deficient 
patients (figure 4). This hypothesis has been partially explored previously, for 
example in the studies by Mammdova-Bach et al and Alshehri et al (140, 141), and 
it appears to have been proven correct by a recent publication using work taken 
from this chapter, alongside complementary techniques (238). This study showed 
that – further to the spreading experiments performed in this chapter – mice 
expressing human GPVI undergo full spreading on a fibrinogen coated surface; 
mouse platelets do not typically undergo full spreading on fibrinogen coated 
surfaces. Other work in this study included surface plasmon resonance experiments 
(clearly showing that fibrinogen binds to monomeric but not dimeric GPVI),  Ca2+ 
mobilisation assays (showing clear calcium increases following fibrinogen 
stimulation of human GPVI expressing murine platelets), and flow adhesion 
experiments (describing an impairment in platelet aggregate growth on a fibrinogen 
coated surface) using human GPVI expressing murine platelets pre-treated with a 
GPVI blocking antibody fragment.  
 
The data from this chapter alongside that performed in the above study clearly 
describe the presence of a significant interaction between fibrinogen and GPVI. 
Interestingly, both fibrinogen and fibrin have been shown to bind to monomeric GPVI 
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rather than dimeric GPVI with almost equal binding affinities (237, 238), raising a 
number of interesting questions and opening several novel avenues for research. 
For example, what is the physiological rationale behind GPVI binding to collagen, 
fibrinogen and fibrin, which are all exposed or expressed at distinct times during 
thrombus formation? Furthermore, what is the impact of the preferential binding of 
fibrinogen and fibrin to monomeric GPVI, when GPVI dimerisation and clustering 
are integral steps for collagen induced GPVI-mediated platelet activation? It will be 
interesting to further characterise these interactions, and to determine any 
physiological or pathophysiological roles which they may play.  
 
Overall, the data in this chapter demonstrates that GPVI is a signalling receptor not 
just for collagen and CRP but also for fibrin, and that a complete loss of surface 
GPVI expression abolishes the responsiveness of platelets to all three agonists. It 
has also contributed significantly to the finding that GPVI appears to interact with 
fibrinogen, and whilst this interaction does not appear to catalyse any robust platelet 
activity or signal transduction in suspension, it appears to induce activation and 
platelet spreading when interacting with fibrinogen adhered to a surface (figure 4). 
This disparity in stimulatory capability is likely due to the simulated cross-linked 
nature of fibrinogen when incubated on a surface, compared to the presence of 
monomeric fibres in suspension. Whilst the lack of response to collagen and fibrin 
in GPVI-/- platelets is apparent in a barrage of platelet specific activation assays,  
there appeared to be no differences in the kinetics of thrombus formation or in 
thrombus composition in a modified clot retraction assay, in keeping with the 
literature which suggests that a deficiency in GPVI does not appear to induce any 
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thrombotic complications or severe bleeding diatheses (257, 258). The results from 
the modified clot retraction assay should be interpreted cautiously however, as only 
a visual assessment was performed and more in-depth analysis is required to 
generate definitive data from these experiments.  
 
It will be interesting to assess in further detail the full physiological effects of a loss 
of GPVI on haemostatic capability, particularly any differences that may be present 
between collagen, fibrin and fibrinogen mediated GPVI activation. It would also be 
of potential interest to compare heterozygous and homozygous patients to 
determine the critical number of GPVI molecules required at the platelet surface to 
sustain signalling and platelet activation, as described above. Overall, the data in 
this thesis chapter has identified and confirmed fibrin and fibrinogen as novel 
agonists for GPVI and raises numerous possibilities for further research into the role 
of the novel GPVI-fibrin and GPVI-fibrinogen interactions in haemostasis, and the 
potential dual role for the receptor in both initial thrombus formation as well as 
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6.1 Key Results Summary 
 
The main aims of this thesis were to: 
• Investigate any potential adapter function of Syk, and explore tyrosine 
phosphorylation events downstream of GPVI and CLEC-2 using a novel Syk 
kinase-dead transgenic mouse model (Syk K396R), 
• Explore the known hyporeactivity of neonatal platelets, particularly in 
response to collagen, and determine if this impaired responsiveness extends 
to CLEC-2 induced platelet activation 
• Investigate the possibility that fibrin may be a novel ligand for GPVI 
 
Throughout this thesis, I have performed experiments against the above aims, and 
the results are summarised briefly below. Firstly, using a novel kinase-dead mouse 
model, I have shown that for platelet activation following both GPVI and CLEC-2 
stimulation, a functional Syk kinase-domain is integral. Whilst some phosphorylation 
is maintained on several key regulatory tyrosine residues throughout Syk (176-181, 
183) in the absence of a functional kinase domain. this maintenance of potential 
adapter function is does not appear to be correlated with downstream signal 
transduction or functional responses (figure 3.6). 
 
Secondly, using mice at different embryonic and postnatal developmental stages, I 
have shown that platelets are hyporeactive to (hem)ITAM stimulation via GPVI and 
CLEC-2, but not GPCR stimulation throughout gestation and early postnatal life. 
Furthermore, I have shown that the hyporeactivity following GPVI and CLEC-2 
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stimulation is only partially correlated with reductions in the surface expression of 
the two receptors. I have also shown that a model of de novo platelet production 
following depletion partially reconstitutes the platelet phenotype observed in 
developing mice  
 
Lastly, using platelets from two un-related families in Chile who have presented with 
the same GPVI mutation – an adenine insertion (c.711_712insA) resulting in a 
premature stop codon - I have confirmed that fibrin is an agonist for GPVI, and have 
presented evidence that fibrinogen is also an agonist for GPVI. Lastly, despite the 
above results, GPVI-/- patients appeared to display normal clot retraction kinetics 
and thrombus compositions, although more experiments and in-depth analysis is 
required to confirm these results.  
6.2 Conclusions and Discussion 
 
The data in chapter 3 of this thesis has shown that for platelet activation following 
both GPVI and CLEC-2 stimulation, a functional Syk kinase-domain is integral. It 
appears that, despite the differences in reliance on Syk for proximal signalling 
events downstream of GPVI and CLEC-2 – with CLEC-2 being reliant on Syk for 
initial hemITAM phosphorylation (151) – both pathways are equally reliant on the 
kinase function of Syk for downstream signalling and platelet functional responses. 
This data furthers the body of information regarding the regulation of Syk following 
receptor engagement, which includes cell line studies describing the importance of 
a functional Syk kinase-domain in supporting signalling (263), alongside in vitro and 
in vivo studies assessing the novel Syk regulatory mechanisms (136, 236). 
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However, whilst the experiments performed within chapter 3 clearly demonstrate 
that a loss of Syk kinase function abolishes platelet functional responses following 
GPVI and CLEC-2 stimulation, the current work only assesses specific tyrosine 
residue phosphorylation as a surrogate marker of adapter capability. It would be 
interesting to perform experiments, such as co-immunoprecipitation experiments, to 
determine any differences in the association of Syk with partner proteins involved in 
signal transduction, such as LAT and PLCγ2, alongside other regulators of Syk 
activity such as c-Cbl and TULA-2. Assessment of these known interactions in Syk 
kinase-dead and wild type mice may help to determine which interactions are 
dependent upon auto-phosphorylation of Syk, and also aid in developing our 
knowledge of the organisation of the signalling pathways downstream of GPVI and 
CLEC-2. Overall, it is hoped that this data may help to guide further research and 
possible novel therapeutic design.  
 
As stated, it has been shown that CLEC-2 is integral for development; as described 
mice deficient in CLEC-2 or associated signalling proteins display significant 
lymphatic development defects, and even present with defects in cerebrovascular 
development (22, 23). Alongside this observation, it has previously been shown that 
neonatal platelets display a significant hyporeactivity in response to many typical 
platelet stimuli, notably in response to the GPVI agonist collagen (43, 242).  These 
two observations formed the basis of the hypothesis that, as GPVI signalling is 
apparently impaired in neonates, it is possible that CLEC-2 signalling may also be 
impaired; this impairment would be counterintuitive when considering the important 
of CLEC-2 in development. During the development of this study, it was shown by 
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Baker-Groberg et al that human neonates have significantly reduced responses to 
both CRP and rhodocytin at 24h post-birth (253), seemingly confirming this 
counterintuitive hypothesis, however, only single dose agonists were used, and no 
time-course of reactivity was assessed. Our study is the first to utilise mice at 
different gestational and post-natal time points to determine a time-course of platelet 
hyporeactivity. We also found that there was a significantly reduced response to 
GPVI and CLEC-2 stimulation immediately following birth, however we also showed 
that for CLEC-2 stimulation with rhodocytin, this hyporeactivity could be overcome 
with high doses of agonists; this was not the case for GPVI stimulation with CRP. It 
was also found that CLEC-2 reactivity appeared to recover quicker than GPVI 
reactivity – suggesting the possibility of differential regulation of signalling 
downstream of the two receptors – and although we found reductions in the surface 
expression of GPVI and CLEC-2, these only partially matched the patterns and 
severity of hyporeactivity. Whilst we could not assess the expression and reactivity 
of key downstream signalling proteins using the mouse model – due mainly to the 
low blood volumes available – we did manage to assess these proteins in both term 
and pre-term neonatal humans, in collaboration with the group of Dr Jose Rivera-
Pozo in Spain (255).  
 
From the combined studies, we found that human neonates displayed similar 
impairments in receptor expression and platelet reactivity to the mice, and also that 
pre-term neonates have a worse phenotype than their term counterparts. We also 
managed to assess the expression and reactivity of Syk, LAT and PLCγ2 in these 
samples, and discovered that both expression and phosphorylation of all of these 
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proteins was impaired in neonatal platelets, again with a worse phenotype in pre-
term vs term samples (255). Taken together, these two sets of experiments suggest 
that platelet (hem)ITAM hyporeactivity is likely mediated by both impaired receptor 
expression and impaired expression and function of key signalling molecules, and 
that the reactivity of these pathways is strongly developmentally regulated. 
However, whilst we appear to have described the mechanisms controlling the 
observed hyporeactivity of neonatal platelets to hemITAM agonists, the 
physiological rationale for this phenomenon remains to be elucidated. This is 
particularly important to determine when we consider the importance of CLEC-2 in 
development alongside its described impaired reactivity. One possible explanation 
– lent credence by the observation that infusion of adult, normo-reactive platelets 
into embryonic mice results in almost immediate diffuse thrombosis (254) –  is that 
the vascular environment is significantly different in rapidly developing vessels, 
compared with established vessels as seen in adults. It would be interesting to 
assess the exposure levels of proteins such as collagen and fibrin, which are 
commonly found in the extracellular matrix, in developing embryonic vessels, as this 
might help to determine whether the observed hyporeactivity may be a protective 
mechanism. It is also interesting to consider the reactivity responses to CLEC-2 in 
more detail, as the impaired response appears to be overcome at higher agonist 
concentrations and appears to approach adult reactivity levels quicker than the 
reactivity of GPVI. These results, considered in the context of the current literature, 
raise the hypothesis that platelet reactivity may be dampened throughout 
development to prevent diffuse spontaneous thrombosis (254), but that a currently 
unknown mechanism is present to allow high concentrations of CLEC-2 agonists to 
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overcome this reactivity impairment. However, more work is needed to fully 
elucidate the rationale for reduced platelet hemITAM reactivity in development, and 
explain why this impairment is not correlated with increased incidence rates of 
CLEC-2 mediated developmental dysfunctions. 
 
Finally, building on the work previously describing fibrin as an agonist for GPVI (140, 
141), I have shown that patients with a homozygous mutation in GPVI do not 
respond to fibrin either in suspension or on a surface. Whilst it was hypothesised 
that these patients would display a lack of response to fibrin, the surprise finding 
that GPVI is important for platelet spreading on fibrinogen coated surfaces was 
extremely novel; data from this chapter was formed an integral part in a recently 
published study definitively proving that GPVI can bind fibrinogen (238). We also 
found that, despite impaired fibrin-GPVI and fibrinogen-GPVI interactions in GPVI-/- 
platelets, thrombus formation kinetics and thrombus composition do not appear to 
differ significantly in the absence of GPVI. Whilst it should be noted that only basic 
optical analysis was performed for these experiments, and more in-depth analysis 
is required, these results suggest that GPVI may not be integral for thrombus 
formation – in keeping with current literature.  
 
The finding that both fibrin and fibrinogen can interact with GPVI, alongside the 
traditional interaction with collagen, raises interesting questions regarding the 
timings of these interactions. It is important to determine when each of these 
interactions dominates – i.e. collagen-GPVI interactions are likely to occur during 
initial tethering and activation of platelets at sites of vascular damage whereas fibrin-
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GPVI interactions are likely to occur during thrombus growth and retraction – to 
determine their importance and impact on thrombosis and haemostasis. It will be 
particularly interesting to explore the importance of the fibrinogen-GPVI interaction, 
as it appears to only initiate signal transduction via GPVI when immobilised on a 
surface and not in suspension.  
 
It was previously believed that fibrin and fibrinogen interacted with platelets solely 
via the integrin αIIbβ3, typically seen an adhesion receptor. This is interesting, as it 
raises the question of the role of GPVI; is the receptor most important as a signalling 
receptor, or can it function as an adhesion receptor? It is also interesting to consider 
subsequent work performed in this area, which has shown that fibrin and fibrinogen 
bind with high affinity to the monomeric form of GPVI (237, 238). This data is in 
direct opposition to the mechanism of binding and activation of GPVI following 
collagen stimulation. Collagen has a high affinity for the dimeric form of GPVI, and 
upon binding and activating GPVI induced significant receptor clustering (129, 130). 
These stark differences in binding affinities and GPVI signal regulation again 
suggests distinct roles for GPVI-collagen and GPVI-fibrin(ogen) interactions. 
Further experiments using platelets from the homozygous patients – such as 
biochemical analysis following platelet spreading and super-resolution microscopy 
to assess receptor kinetics and organisation following differential stimulation of 
GPVI – may help to elucidate some of the key differences between these GPVI 
interactions, and provide some hints as to their physiological relevance. 
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6.3 Final Remarks 
 
Overall, these results highlight the fact that despite their apparent involvement in 
significantly different biological processes, the regulation of GPVI, CLEC-2 and their 
common signalling pathway appear to be intimately linked. It has also shown that 
platelet reactivity and composition vary drastically throughout development, which 
is interesting considering their integral role in lymphatic and cerebrovasular 
development. Lastly, it has helped to identify new ligands and regulatory 
mechanisms for GPVI and CLEC-2. 
 
The information uncovered throughout this thesis reinforces the important role that 
platelets play in a diverse range of physiological processes, and also highlights the 
fact that many of the processes controlling and regulating these interactions remain 
incompletely understood. It is hoped that the data generated over the course of this 
body of work may form the basis of further studies to fully elucidate the mechanisms 
controlling the integral contributions of these specs of ‘cellular dust’ in thrombosis, 
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